UNITED STATES
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________________ to ____________________ |
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
||
|
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
|
Emerging growth company
|
U.S. GAAP ☐
|
|
Other ☐
|
If this is an annual report, indicate by check mark whether the Company is a shell company (as defined in Rule 12b-2 of the Exchange Act).
5 | ||
7 | ||
12 | ||
12 | ||
12 | ||
12 | ||
A. |
Reserved. |
12 |
B. |
Capitalization and Indebtedness |
12 |
C. |
Reasons for the Offer and Use of Proceeds
|
13 |
D. |
Risk Factors |
13 |
41 | ||
A. |
History and Development of the Company
|
41 |
B. |
Business Overview |
47 |
C. |
Organizational Structure |
65 |
D. |
Property, Plants and Equipment |
65 |
66 | ||
66 | ||
A. |
Operating Results |
66 |
B. |
Liquidity and capital resources
|
66 |
C. |
Research and development, patents and
licenses, etc |
66 |
D. |
Trend Information |
67 |
E. |
Critical Accounting Estimates |
67 |
80 | ||
A. |
Directors and Senior Management |
80 |
B. |
Compensation |
83 |
C. |
Board Practices |
95 |
D. |
Employees |
102 |
E. |
Share Ownership |
103 |
F. |
Disclosure of a registrant’s action
to recover erroneously awarded compensation |
103 |
103 | ||
A. |
Major Shareholders |
103 |
B. |
Related Party Transactions |
105 |
C. |
Interests of Experts and Counsel
|
107 |
107 | ||
A. |
Consolidated Statements and Other Financial
Information |
107 |
B. |
Significant Changes |
113 |
114 | ||
A. |
Offer and Listing Details |
114 |
B. |
Plan of Distribution |
114 |
C. |
Markets |
114 |
D. |
Selling Shareholders |
114 |
E. |
Dilution |
114 |
F. |
Expenses of the Issue |
114 |
114 | ||
A. |
Share Capital |
114 |
B. |
Memorandum and Articles of Association
|
114 |
C. |
Material Contracts |
119 |
D. |
Exchange Controls |
119 |
E. |
Taxation |
120 |
F. |
Dividends and Paying Agents |
127 |
G. |
Statement by Experts |
127 |
H. |
Documents on Display |
127 |
I. |
Subsidiary Information |
128 |
J. |
Annual Report to Security Holders
|
128 |
128 | ||
128 | ||
128 | ||
128 | ||
129 | ||
A. |
Disclosure Controls and Procedures
|
129 |
B. |
Management’s Annual Report on Internal
Control Over Financial Reporting |
129 |
C. |
Attestation Report of Registered Public
Accounting Firm |
129 |
D. |
Changes in Internal Controls Over Financial
Reporting |
129 |
130 | ||
130 | ||
130 | ||
131 | ||
131 | ||
132 | ||
132 | ||
133 | ||
133 | ||
133 | ||
133 | ||
Risk Management and Strategy |
133 | |
Governance |
134 | |
135 | ||
135 | ||
136 |
|
Legal
Entity |
Jurisdiction
|
Relationship
with the Company |
I.M.C.
Holdings Ltd. (“IMC Holdings”) |
Israel
|
Wholly-owned
subsidiary |
I.M.C.
Pharma Ltd. (“IMC Pharma”) |
Israel
|
Wholly-owned
subsidiary of IMC Holdings |
Focus
Medical Herbs Ltd.(1) (“Focus”)
|
Israel
|
Private
company over which IMC Holdings exercises “de facto control” under IFRS 10 |
R.A.
Yarok Pharm Ltd. (“Pharm Yarok”) |
Israel
|
Wholly-owned
subsidiary of IMC Holdings |
Rosen
High Way Ltd. (“Rosen High Way”) |
Israel
|
Wholly-owned
subsidiary of IMC Holdings |
Revoly Trading and Marketing Ltd. d/b/a Vironna Pharm (“Vironna”)
|
Israel
|
Subsidiary
of IMC Holdings |
Adjupharm GmbH (“Adjupharm”)
|
Germany |
Subsidiary of IMC
Holdings |
Xinteza API Ltd (“Xinteza”)
|
Israel |
Subsidiary of IMC
Holdings |
Shiran Societe Anonyme
(“Greece”) |
Greece |
Subsidiary of IMC
Holdings |
IM Cannabis Holding
NL B.V Netherlands (“IMC Holdings NL”) |
Netherlands |
Wholly-owned subsidiary
of IMC Holdings |
Oranim Plus Pharm Ltd. (“Oranim Plus”) 2)
|
Israel
|
Former
subsidiary of IMC Holdings |
Trichome Financial
Corp. (3) |
Canada |
Former wholly-owned
subsidiary |
I.M.C
Farms Israel Ltd. (“IMC Farms”).
(4) |
Israel
|
Wholly-owned
subsidiary of IMC Holdings |
IMCC
Medical Herbs Ltd. (“IMCC Medical Herbs”)(5)
|
Israel
|
Wholly-owned
subsidiary of IMC Holdings |
High Way Shinua Ltd.
(“High Way Shinua”)(6)
|
Israel |
Subsidiary of IMC
Holdings |
(1) |
Effective February 26, 2024, IMC Holdings exercised its option to acquire a 74% ownership stake in Focus. |
(2) |
Effective April 16, 2024, IMC Holdings no longer holds shares in Oranim Plus. For more information, please see “Item
4B. History and Development of the Company Important Events in the Development of the Business in Fiscal 2024 to the date of this Annual
Report”. |
(3) |
Discontinued operations. Please see note 25 in the 2024 Annual Financial Statements |
(4) |
On January 8, 2025, the Israeli Companies Registrar approved the liquidation of IMC Farms, which will be
completed within 100 days from the date of approval. |
(5) |
On January 13, 2025, the Israeli Companies Registrar approved the liquidation status of IMCC Medical Herbs,
stating that the liquidation will be completed within 100 days from the date of approval. |
(6) |
On December 14, 2023, Israeli Companies Registrar approved the liquidation status of High Way Shinua, which
liquidation was completed on March 23, 2024. |
• |
the Company’s business objectives and milestones and the anticipated timing of execution; |
• |
the performance of the Company’s business, strategies and operations; |
• |
the Company’s intentions to expand the business, operations and potential activities of the Company; |
• |
the Company’s plans to expand its sales channels, distribution, delivery and storage capacity, and reach to medical cannabis
patients; |
• |
the competitive conditions of the cannabis industry and the growth of medical or adult-use recreational cannabis markets in the jurisdictions
in which the Company operates; |
• |
the competitive conditions of the industry, including the Company’s ability to maintain or grow its market share and maintain
its competitive advantages; |
• |
statements relating to the Company’s commitment to responsible growth and compliance with the strictest regulatory environments;
|
• |
the Company’s focus on providing premium cannabis products to medical patients in the jurisdictions in which the Company conducts
business and any other jurisdiction in which the Company may conduct business in the future; |
• |
the Company’s plans to amplify its commercial and brand power to become a global high-quality cannabis player; |
• |
the Company’s primary goal of sustainably increasing revenue in its core markets; |
• |
the demand and momentum in the Company’s Israeli and Germany operations; |
• |
how the Company intends to position its brands; |
• |
the efficiencies and synergies of the Company as a global organization with domestic expertise in Israel and Germany; |
• |
expectations that providing high-quality, reliable supply to the Company’s customers and patients will lead to recurring sales;
|
• |
expectations related to the Company’s introduction of new Stock Keeping Units (“SKUs”);
|
• |
anticipated cost savings from the reorganization of the Company and the completion thereof upon the timelines disclosed herein;
|
• |
geographic diversification and brand recognition and the growth of the Company’s brands in the jurisdictions that the Company
operates in or may expand to; |
• |
expectations related to the Company’s ability to address the ongoing needs and preferences of medical cannabis patients;
|
• |
the Company’s retail presence, distribution capabilities and data-driven insights; |
• |
the future impact of the Regulations Amendment (as defined herein) regarding the transition reform from licenses to prescriptions
for medical treatment of cannabis; |
• |
the Company’s continued partnerships with third party suppliers and partners and the benefits thereof; |
• |
the Company’s ability to achieve profitability in 2025; |
• |
the number of patients in Israel licensed by the Israeli Ministry of Health (“MOH”)
to consume medical cannabis; |
• |
expectations relating to the number of patients paying out-of-pocket for medical cannabis products in Germany; |
• |
the anticipated decriminalization or legalization of adult-use recreational cannabis in Israel and Germany; |
• |
expectations related to the demand and the ability of the Company to source premium and ultra-premium cannabis products exclusively
and competition in this product segment; |
• |
the anticipated impact of inflation and liquidity on the Company’s performance; |
• |
expectations with respect to the Company’s operating budget and the assumptions related thereto; |
• |
expectations relating to the Company as a going concern and its ability to conduct business under the ordinary course of operations;
|
• |
expectations related to the collection of the payment awarded in Test Kits Appeal, and the potential outcome of the Test Kits Appeal
(as defined herein); |
• |
the continued listing of the common shares in the capital of the Company (“Common Shares”)
on the Nasdaq Stock Market (“Nasdaq”) and Canadian Securities Exchange (“CSE”);
|
• |
cannabis licensing in the jurisdictions in which the Company operates; |
• |
the renewal and/or extension of the Company’s licenses; |
• |
the Company’s anticipated operating cash requirements and future financing needs; |
• |
the Company’s expectations regarding its revenue, expenses, profit margins and operations; |
• |
the expected increase in revenue and margins in its Israeli medical cannabis market activities arising from its acquisitions;
|
• |
future opportunities for the Company in Israel, particularly in the retail and distribution segments of the cannabis market;
|
• |
future expansion and growth opportunities for the Company in Germany and Europe and the timing of such; and |
• |
contractual obligations and commitments. |
• |
the Company has the ability to achieve its business objectives and milestones under the stated timelines; |
• |
the Company will succeed in carrying out its business, strategies and operations; |
• |
the Company will realize upon its intentions to expand the business, operations and potential activities of the Company; |
• |
the Company will expand its sales channels, distribution, delivery and storage capacity, and reach to medical cannabis patients;
|
• |
the competitive conditions of the cannabis industry and the growth of medical or adult-use recreational cannabis in the jurisdictions
in which the Company operates; |
• |
the competitive conditions of the industry will be favorable to the Company, and the Company has the ability to maintain or grow
its market share and maintain its competitive advantages; |
• |
the Company will commit to responsible growth and compliance with the strictest regulatory environments; |
• |
the Company will remain focused on providing premium cannabis products to medical patients in the jurisdictions in which the Company
conducts business and any other jurisdiction in which the Company may conduct business in the future; |
• |
the Company has the ability to amplify its commercial and brand power to become a global high-quality cannabis player; |
• |
the Company will maintain its primary goal of sustainably increasing revenue in its core markets; |
• |
the demand and momentum in the Company’s Israeli and Germany operations will be favorable to the Company; |
• |
the Company will carry out its plans to position its brands as stated; |
• |
the Company has the ability to realize upon the stated efficiencies and synergies the Company as a global organization with domestic
expertise in Israel and Germany; |
• |
providing a high-quality, reliable supply to the Company’s customers and patients will lead to recurring sales; |
• |
the Company will introduce new SKUs; |
• |
the Company will realize the anticipated cost savings from the reorganization; |
• |
the Company has the ability to achieve geographic diversification and brand recognition and the growth of the Company’s brands
in the jurisdictions that the Company operates in or may expand to; |
• |
the Company’s has the ability to address the ongoing needs and preferences of medical cannabis patients; |
• |
the Company has the ability to realize upon its retail presence, distribution capabilities and data-driven insights; |
• |
the future impact of the Regulations Amendment will be favorable to the Company; |
• |
the Company will maintain its partnerships with third parties, suppliers and partners; |
• |
the Company has the ability to achieve profitability in 2025; |
• |
the accuracy of number of patients in Israel licensed by the MOH to consume medical cannabis; |
• |
the accuracy of the number of patients paying out-of-pocket medical cannabis products in Germany; |
• |
the anticipated decriminalization or legalization of adult-use recreational cannabis in Israel and Germany will occur; |
• |
the Company has the ability to source premium and ultra-premium cannabis products exclusively and competition in this product segment;
|
• |
the anticipated impact of inflation and liquidity on the Company’s performance will be as forecasted; |
• |
the accuracy with respect to the Company’s operating budget and the assumptions related thereto; |
• |
the Company will remain as going concern; |
• |
a favorable outcome with respect to the collection of the awards in successful judgements, and the success of other ongoing claims
the Company is involved in; |
• |
the Company’s Common Shares will remain listed on the Nasdaq and CSE; |
• |
the Company’s ability to maintain cannabis licensing in the jurisdictions in which the Company operates; |
• |
the Company has the ability to obtain the renewal and/or extension of the Company’s licenses; |
• |
the Company has the ability to meet operating cash requirements and future financing needs; |
• |
the Company will meet or surpass its expectations regarding its revenue, expenses, profit margins and operations; |
• |
the Company will have the ability to collect the payment awarded in Test Kits Appeal; |
• |
the Company will increase its revenue and margins in its Israeli medical cannabis market activities arising from its acquisitions;
|
• |
the Company has the ability to capitalize on future opportunities for the Company in Israel, particularly in the retail and distribution
segments of the cannabis market; |
• |
the Company will carry out its future expansion and growth opportunities for the Company in Germany and Europe and the timing of
such; and |
• |
the Company will fulfill its contractual obligations and commitments. |
• |
the Company’s inability to achieve its business objectives and milestones under the stated timelines; |
• |
the Company inability to carry out its business, strategies and operations; |
• |
the Company’s inability to realize upon its intentions to expand the business, operations and potential activities of the Company;
|
• |
the Company will not expand its sales channels, distribution, delivery and storage capacity, and reach to medical cannabis patients;
|
• |
the competitive conditions of the cannabis industry and the growth of medical or adult-use recreational cannabis markets will be
unfavorable to the Company in the jurisdictions in which the Company operates; |
• |
the competitive conditions of the industry will be unfavorable to the Company, and the Company’s inability to maintain or grow
its market share and maintain its competitive advantages; |
• |
the Company will not commit to responsible growth and compliance with the strictest regulatory environments; |
• |
the Company’s inability to remain focused on providing premium cannabis products to medical patients in the jurisdictions in
which the Company conducts business and any other jurisdiction in which the Company may conduct business in the future; |
• |
the Company inability to amplify its commercial and brand power to become a global high-quality cannabis player; |
• |
the Company will not maintain its primary goal of sustainably increasing revenue in its core markets; |
• |
the demand and momentum in the Company’s Israeli and Germany operations will be unfavorable to the Company; |
• |
the Company will not carry out its plans to position its brands as stated; |
• |
the Company’s inability to realize upon the stated efficiencies and synergies of the Company as a global organization with
domestic expertise in Israel and Germany; |
• |
providing a high-quality, reliable supply to the Company’s customers and patients will not lead to recurring sales; |
• |
the Company will not introduce new SKUs; |
• |
the Company’s inability to realize upon the anticipated cost savings from the reorganization; |
• |
the Company’s inability to achieve geographic diversification and brand recognition and the growth of the Company’s brands
in the jurisdictions that the Company operates in or may expand to; |
• |
the Company’s inability to address the ongoing needs and preferences of medical cannabis patients; |
• |
the Company’s inability to realize upon its retail presence, distribution capabilities and data-driven insights; |
• |
the future impact of the Regulations Amendment will be unfavorable to the Company; |
• |
the Company will not maintain its partnerships with third party suppliers and partners; |
• |
the Company’s inability to achieve profitability in 2025; |
• |
the inaccuracy of number of patients in Israel licensed by the MOH to consume medical cannabis; |
• |
the inaccuracy of the number of patients paying out-of-pocket for medical cannabis products in Germany; |
• |
the anticipated decriminalization or legalization of adult-use recreational cannabis in Israel and Germany will not occur;
|
• |
the Company’s ability to source premium and ultra-premium cannabis products exclusively and competition in this product segment;
|
• |
the anticipated impact of inflation and liquidity on the Company’s performance will not be as forecasted; |
• |
the inaccuracy with respect to the Company’s operating budget and the assumptions related thereto; |
• |
the Company will not remain as going concern; |
• |
an unfavorable outcome of legal proceedings the Company is involved in; |
• |
an unfavorable outcome with respect to the collection of the award pursuant to the Test Kits Appeal and the Company being unsuccessful
in other ongoing claims the Company is involved in; |
• |
the Company’s Common Shares will not remain listed on the Nasdaq and CSE; |
• |
the Company’s inability to maintain cannabis licensing in the jurisdictions in which the Company operates; |
• |
the Company’s inability to obtain the renewal and/or extension of the Company’s licenses; |
• |
the Company’s inability to meet operating cash requirements and future financing needs; |
• |
the Company will not meet or surpass its expectations regarding its revenue, expenses, profit margins and operations; |
• |
the Company will not increase its revenue and margins in its Israeli medical cannabis market activities arising from its acquisitions;
|
• |
the Company’s ability to capitalize on future opportunities for the Company in Israel, particularly in the retail and distribution
segments of the cannabis market; |
• |
the Company will not carry out its future expansion and growth opportunities for the Company in Germany and Europe and the timing
of such; and |
• |
the Company will not fulfill its contractual obligations and commitments. |
1) |
the Company receiving economic benefits from Focus (and the terms of the Commercial Agreements (as defined herein) cannot be changed
without the approval of the Company); |
2) |
the Company having the option to purchase the divested 74% interest in Focus held by Oren Shuster, the Chief Executive Officer, director
and a promoter of the Company, and Rafael Gabay, a former consultant director, a former consultant and a promoter of the Company;
|
3) |
Messrs. Shuster and Gabay each being a director of Focus (while Mr. Shuster concurrently being a director, officer and substantial
shareholder of the Company and Mr. Gabay concurrently being a substantial shareholder of the Company); and |
4) |
the Company providing management and support activities to Focus through the Services Agreement (as defined herein). |
● |
diversion of management time and focus from operating our business to addressing acquisition integration challenges; |
● |
coordination of research and development and sales and marketing functions; |
● |
retention of employees from the acquired company; |
● |
cultural challenges associated with integrating employees from the acquired company into our organization; |
● |
integration of the acquired company's accounting, management information, human resources, and other administrative systems;
|
● |
the need to implement or improve controls, procedures, and policies at a business that prior to the acquisition may have lacked effective
controls, procedures, and policies; |
● |
potential write-offs of intangible assets or other assets acquired in transactions that may have an adverse effect on our operating
results in a given period; |
● |
liability for activities of the acquired company before the acquisition, including patent and trademark infringement claims, violations
of laws, commercial disputes, tax liabilities, and other known and unknown liabilities; and |
● |
litigation or other claims in connection with the acquired company, including claims from terminated employees, consumers, former
stockholders, or other third parties. |
• |
$1,560 (NIS 4 million) will be extended as a loan with a six-month grace period, after which repayment
will be made in 31 monthly installments commencing September 10, 2025. The principal loan will not require a personal guarantee and will
bear an interest at a rate of prime plus+2.9% to be paid monthly, commencing April 20, 2025. |
• |
The remaining $390 (NIS 1 million) will be extended as a credit line from March 19, 2025, to March 12, 2026. |
• |
We began working with a new processing facility to improve gross margin and enhance business flexibility. |
• |
Reducing shipping and distribution costs through efficiency measures, service provider replacements, and outsourcing. |
• |
Streamlining operations by reducing headcount and closing the trading house to optimize costs. |
• |
Addressing higher costs and operational challenges due to flight disruptions caused by the Iron Swords War. |
• |
$1,560 (NIS 4 million) will be extended as a loan with a six-month grace period, after which repayment
will be made in 31 monthly installments commencing September 10, 2025. The principal loan will not require a personal guarantee and will
bear an interest at a rate of prime plus+2.9to be paid monthly, comencing April 20, 2025. |
• |
The remaining $390 (NIS 1 million) will be extended as a credit line from March 19, 2025, to March 12, 2026. |
- |
Shai Shemesh, resigned as Chief Financial Officer of the Company and Itay Vago, was appointed as Chief Financial Officer of the Company
to fill the vacancy created by Shai Shemesh’s resignation. |
- |
Rinat Efrima, resigned as Chief Executive Officer of IMC Holdings and Eyal Fisher was appointed as the General Manager of IMC Holdings
to fill the vacancy created by Ms. Efrima’s resignation. Mr. Fisher previously held the position of Sales Director of IMC Holdings
prior to his appointment as General Manager. |
- |
Yael Harrosh resigned as Chief Legal and Operations Officer of the Company and Michal Lebovitz was appointed on April 14, 2023 as
General Counsel of the Company to fill the vacancy created by Mr. Harrosh’s resignation. |
- |
The Craft Collection – IMC brand’s premium product line with indoor-grown, hand-dried
and hand-trimmed high-THC cannabis flowers. The Craft Collection includes exotic and unique cannabis strains such as Sup.S. |
- |
The Top-Shelf Collection – IMC’s premium product line, which offers indoor-grown,
high-THC cannabis flowers with strains such as Lemon Rocket, Diesel Drift, Tropicana Gold, Lucy Dreamz, Santa Cruz, Or’enoz, and
Banjo. Inspired by the 1970’s cannabis culture in America, the Top-Shelf Collection targets the growing segment of medical patients
who are cannabis culture enthusiasts. |
- |
The Signature Collection –IMC brand’s high-quality product line with greenhouse-grown
or indoor grown, high-THC cannabis flowers. The Signature Collection currently includes well known proprietary cannabis dried flowers
such as Chemchew, Rockabye, FLO OG, Roma T15, Roma T20, Karma lada, Sydney, MOTORBRTH and B.F LMO, all an indoor-grown flowers.
|
- |
The Full Spectrum Extracts – IMC brand’s full spectrum, strain-specific cannabis
extracts, includes high-THC Roma® T20 oil and OIL GLTO 33. |
- |
Roma® Product Portfolio – IMC’s Roma portfolio also includes oils. IMC’s
Roma® strain is a high-THC medical cannabis flower that offers a therapeutic continuum and is known for its strength and longevity
of effect. |
- |
WAGNERS™ – this brand launched in Israel in Q1 2022, with indoor-grown cannabis
imported from Canada. The WAGNERS™ brand was the first international premium, indoor-grown brand introduced to the Israel cannabis
market, at a competitive price point. The WAGNERS™ brand includes Cherry Jam, Rainforest Crunch, Tiki Rain, Pink Buba and Silverback#4.
|
- |
BLKMKT™ – this is the Company’s second Canadian brand. It is a super-premium
product line with indoor-grown, hand-dried and hand-trimmed high-THC cannabis flowers. The BLKMKT™ includes BLK MLK, YA HEMI, PURPLE
RAIN, JEALOUSY, Hemi GLTO, RAINBOW P, GUVA BOBA, Sunsets.rudel, Park fire OG and Upside down C. |
- |
LOT420 – this brand launched in Israel in
Q2 2023, with super-premium indoor-grown cannabis imported from Canada with high-THC. The
LOT420 brand includes GLTO 33, Apps and Bans and O.C. The Company ceased selling Atomic APP.
|
- |
The PICO collection (minis) - Under the BLKMKT™ and LOT420 brands, the Company launched
a new type of product (small flowers) in 2023, which is a super-premium indoor-grown cannabis imported from Canada with high-THC. The
PICO collection includes the following products: PICO PURPLE RAIN, PICO YA HEMI, PICO JEALOUSY, Pico upside Down, PICO RAIN BOW, Pico
California love, PICO BLK MLK and PICO Bacio Glto. |
- |
Flower – In Q2 2024, the Company launched a super-premium indoor-grown cannabis imported
from Canada with high-THC. The Flower brand includes cannabis strains California Love and Face Sherb. |
Revenues
from Continuing operations - By Product Type | ||||
Financial Year |
Medical Cannabis Products |
Adult-Use Recreational Cannabis Products |
Other Products |
Total |
2024 |
$51,355 |
- |
$2,696 |
$54,031 |
2023 |
$44,246 |
- |
$4,558 |
$48,804 |
2022 |
$48,384 |
- |
$5,951 |
$54,335 |
Revenues from Continuing operations - by geographic market
| |||
Financial Year |
Israel |
Germany |
Total |
2024 |
$38,523 |
$15,508 |
$54,031 |
2023 |
$43,316 |
$5,488 |
$48,804 |
2022 |
$50,500 |
$3,835 |
$54,335 |
1. |
Change in the prescription process: patients with a wide range of diseases and medical conditions from Oncology to Parkinsons will
no longer be required to obtain a license to receive medical cannabis. Patients will receive a prescription similar to those for other
prescription medications. Pain and PTSD are not included in the April 2024 Regulatory Reform yet. |
2. |
Medical cannabis will now be prescribed through the HMO's, Israel's public healthcare system: until the April 2024 Regulatory Reform,
cannabis could not be prescribed through the HMO's which cover the majority of the Israeli population. |
3. |
The number of prescribing physicians is expected to increase: as of today, HMO physicians, who are dully trained and certified within
their field of expertise, can prescribe medical cannabis as a first line treatment, as opposed to a last resort, based on medical discretion
for the approved indications. |
4. |
The cost for prescription is anticipated to be reduced: the Ministry of Health limited the cost for a medical cannabis prescription.
|
Level 1 |
- |
quoted prices (unadjusted) in active markets for identical assets or liabilities.
|
Level 2 |
- |
inputs other than quoted prices included within Level 1 that are observable directly
or indirectly. |
Level 3 |
- |
inputs that are not based on observable market data (valuation techniques that use
inputs that are not based on observable market data).
|
Name |
Position(s) with the
Company |
Other Directorships
|
Date of Initial Appointment
|
Oren Shuster(4)
|
CEO, Executive Chairman, and Director
|
IMC Holdings; Focus; Pharm Yarok; Rosen High Way; IMC Pharma; IMC Farms; Ewave Group Ltd (“Ewave”) and its subsidiaries |
October 11, 2019 |
Moti Marcus(2)(3)(4)
|
Director |
Nil |
September 12, 2022 |
Einat Zakariya(2)(3)(4)
|
Director |
Nil |
September 12, 2022 |
Brian Schinderle(2)(3)
|
Director |
Nil |
February 22, 2021 |
Shmulik Arbel |
Director |
Delta Capita Group, London, Canada Global
|
September 9, 2024 |
Uri Birenberg |
CFO |
Nil |
October 10, 2023 |
Eyal Fisher |
CEO of IMC Holdings and each of the Israeli
Subsidiaries |
Nil |
March 8, 2023 |
Michal Lebovitz Nissimov |
General Counsel |
Nil |
April 14, 2023 |
Richard Balla |
CEO of Adjupharm, a wholly owned subsidiary
of the Company |
Nil |
October 11, 2019 |
(1) |
Information furnished by the respective individual. |
(2) |
Member of the Audit Committee. |
(3) |
Member of Compensation Committee. |
(4) |
Member of the Governance and Nomination Committee. |
(1) |
Oren Shuster, CEO, Executive Chairman and a director of the Company. |
(2) |
Uri Birenberg, CFO of the Company. |
(3) |
Eyal Fisher, CEO of the IMC Holdings and each of the Israeli Subsidiaries; |
(4) |
Richard Balla, CEO of Adjupharm, a wholly owned subsidiary of the Company; and |
(5) |
Michal Lebovitz Nissimov, Company's General Counsel and secretary |
1. |
base salary; |
2. |
cash bonuses; and/or |
3. |
long-term incentives. |
1. |
Base Salary |
2. |
Cash Bonuses |
3. |
Long Term Incentives |
(a) |
the maximum number of RSUs available for grant to any one person under the RSU Plan and any other Securities Based Compensation Arrangements
of the Company in a 12-month period is 5% of the total number of Common Shares then outstanding on a non-diluted basis; and |
(b) |
the maximum number of Common Shares issuable to insiders of the Company (as a group) under the RSU Plan, together with any other
Common Shares issuable under any other Securities Based Compensation Arrangements, shall not exceed at any time or within any 12-month
period, 10% of the issued and outstanding Common Shares on a non-diluted basis at the time of grant. |
(a) |
increase the number of Common Shares which may be issued pursuant to the RSU Plan, other than by virtue of a change in Common Shares,
whether by reason of a stock dividend, consolidation, subdivision or reclassification which adjustment may be made by the Board or Compensation
Committee for the number of Common Shares available under the RSU Plan and the number of Common Shares subject to RSUs; |
(b) |
amend the definition of “Participant” under the RSU Plan which would have the potential of narrowing, broadening or increasing
insider participation; |
(c) |
amendments to cancel and reissue RSUs; |
(d) |
amendments to the list of amendments to the RSU Plan or RSUs requiring requisite regulatory and shareholder approval and those subject
to requisite regulatory approval (where required) but not subject to shareholder approval; |
(e) |
amendments that extend the term of an RSU; |
(f) |
amendments to the participation limits including: the maximum number of shares issuable under the RSU Plan, limitations on grants
of RSUs to any one person in a 12-month period, grants within a one-year period to insiders, and the number of shares issuable to a person
providing investor relations activities in any 12-month period; and |
(g) |
amendments to the RSU Plan that would permit RSUs, or any other right or interest of a RSU Participant under the RSU Plan, to be
assigned or transferred, other than for normal estate settlement purposes. |
(a) |
amendments of a housekeeping nature. |
(b) |
amendments to the vesting provisions of a RSU or the RSU Plan. |
(c) |
amendments to the definitions, other than such definitions noted above. |
(d) |
amendments to reflect changes to applicable securities laws; and |
(e) |
amendments to ensure that the RSUs granted under the RSU Plan will comply with any provisions respecting income tax and other laws
in force in any country or jurisdiction of which a RSU Participant to whom a RSU has been granted may from time to time be a resident,
citizen or otherwise subject to tax therein. |
December 31, 2020
|
December 31, 2021
|
December 31, 2022
|
December 31, 2023
|
December 31, 2024
| |
IM Cannabis Corp.
|
$100.00 |
$42.03 |
$1.29 |
$0.46 |
$0.54 |
CSE Composite Index
|
$100.00 |
$171.57 |
$132.1 |
$41.3 |
$33.71 |
1. |
Einat Zakariya (Chair); |
2. |
Brian Schinderle; and |
3. |
Moti Marcus, |
• |
Salary Benchmarking for Management Positions – Conducting a comparative analysis of
executive salary levels based on a tailored sample of companies. This includes the CEO and senior management positions, with a breakdown
of base salary, bonuses, and equity compensation. |
• |
Compensation Analysis for International Operations – Assessing salary levels for executives
in Adjupharm, using MERCER and Accumulate market data. This includes benchmarking compensation components such as base salary, bonuses,
and equity grants. |
• |
Equity Grant Policy Review – Evaluating the Company’s equity compensation strategy
for Board members and executives, including grant methods, frequency, and valuation. |
• |
Equity Compensation Policy Development – Establishing an equity-based compensation framework,
including: |
o |
Defining a capital compensation strategy. |
o |
Structuring an allocation model for existing and new employees, from the CEO and Board members downward. |
o |
Setting guidelines for equity content and reallocation policies. |
o |
Developing a multi-year allocation plan; and |
o |
Supporting Compensation Committee approval processes. |
Name and Principal Position
|
Year |
Salary
($)(1)
|
Share-Based Awards
($) |
Option-Based Awards
($)(2)
|
Non-Equity Incentive
Plan Compensation
($) |
Pension Value
($) |
All Other
Compensation ($) |
Total
Compensation ($) | |
Annual Incentive Plans
|
Long-Term Incentive
Plans | ||||||||
Oren Shuster(3)
CEO,
Executive Chairman and Director |
2024 |
484,697 |
Nil |
45,591 |
Nil |
Nil |
Nil |
Nil |
530,288 |
2023 |
476,266 |
Nil |
331,802 |
Nil |
Nil |
Nil |
Nil |
818,068 | |
2022 |
506,244 |
Nil |
1,110,057 |
Nil |
Nil |
Nil |
Nil |
1,616,301 | |
Uri Birenberg(4)
CFO
|
2024 |
330,238 |
Nil |
Nil |
Nil |
Nil |
Nil |
26,064 |
356,302 |
2023 |
73,558 |
Nil |
Nil |
Nil |
Nil |
Nil |
Nil |
73,558 | |
2022 |
Nil |
Nil |
Nil |
Nil |
Nil |
Nil |
Nil |
Nil | |
Eyal Fisher(5)
CEO of the IMC Holdings
and each of the Israeli Subsidiaries |
2024 |
262,198
|
Nil |
628 |
Nil |
Nil |
Nil |
34,966 |
297,164 |
2023 |
216,998 |
Nil |
1,693
|
Nil |
Nil |
Nil |
Nil |
216,998 | |
2022 |
215,586 |
Nil |
4,381 |
Nil |
Nil |
Nil |
Nil |
217,279 | |
Richard Balla
CEO
of Adjupharm |
2024 |
193,608 |
Nil |
Nil |
88,908 |
Nil |
Nil |
31,035 |
313,551 |
2023 |
175,385 |
Nil |
Nil |
87,692 |
Nil |
Nil |
30,895 |
293,972 | |
2022 |
164,186 |
Nil |
37 |
Nil |
Nil |
Nil |
29,066 |
193,289 | |
Michal Lebovitz Nissimov
General Counsel and
secretary(6) |
2024 |
192,877 |
Nil |
828 |
Nil |
Nil |
Nil |
Nil |
193,705 |
2023 |
119,088 |
Nil |
1,099 |
Nil |
Nil |
Nil |
Nil |
120,187 | |
Marc Lustig,
former Executive Chairman(7)
|
2024 |
22,400 |
Nil |
Nil |
Nil |
Nil |
Nil |
Nil |
22,400 |
2023 |
129,920 |
79,959 |
Nil |
Nil |
Nil |
Nil |
Nil |
209,879 |
(1) |
Each of Messrs. Shuster, Birenberg, Fisher, and Mrs. Lebovitz Nissimov received their compensation in NIS and Mr. Balla received
his compensation in Euros. All salaries were converted to CDN pursuant to the average Bank of Canada rate for the applicable fiscal year.
|
(2) |
The Company used the Black-Scholes pricing model as the methodology to calculate the grant date fair value, and relied on the following
the key assumptions and estimates for each calculation under the following assumptions: (i) risk free interest rate of 0.42% to 4.21%
(ii) expected dividend yield of 0%; (iii) expected volatility of 76.28% to 82.31%; and (iv) a term of 2 to 10 years. The Black-Scholes
pricing model was used to estimate the fair value as it is the most accepted methodology. |
(3) |
Oren Shuster, through Ewave, a company in which he controls, entered into a consulting agreement with the Company pursuant to which
he is paid NIS 108,350 plus VAT per month (approximately $40,390 plus tax per month) in consideration of his CEO services provided to
the Company. Mr. Shuster did not earn consideration for his role as Chairman and nor as a director of the Company during the fiscal years
ended December 31, 2024, 2023 and 2022. |
(4) |
Mr. Birenberg was appointed as CFO of the Company effective October 10, 2023. |
(5) |
Mr. Fisher was appointed as CEO of the IMC Holdings and each of the Israeli Subsidiaries effective March 15, 2023. |
(6) |
Michal Lebovitz Nissimov was appointed as Company General Counsel and Secretary effective April 14, 2023. |
(7) |
50,065300,393 Common Shares and 23,020 Warrants are held by Marc Lustig directly and 105,040 Common Shares and 495,74282,624 Warrants
are held indirectly through L5 Capital, a privately held entity of which Mr. Lustig owns and controls 100% of the outstanding voting rights.
Mr. Lustig resigned from his role as a director effective June 5, 2024. |
Option-based
Awards |
Share-based
Awards | ||||||
Name
|
Number
of securities underlying unexercised Options
(#)(1)
|
Option
exercise price
($)
|
Option
expiration date |
Value
of unexercised
in-the-money Options ($)(2)
|
Number
of shares or units of shares that have not vested
(#)
|
Market
or payout value of share-based awards that have not vested(4)
($)
|
Market or payout value
of vested share-based awards not paid out or distributed
($) |
Oren Shuster |
21,875 |
3.00 |
October 4, 2026 |
5,469 |
Nil |
Nil |
Nil |
Uri Birenberg |
Nil |
Nil |
Nil |
Nil |
Nil |
Nil |
Nil |
Eyal Fisher |
167 |
3.00 |
October 4, 2026 |
42 |
Nil |
Nil |
Nil |
Richard Balla |
1,500 |
16.00 |
July 30, 2029 |
Nil |
Nil |
Nil |
Nil |
Michal Lebovitz Nissimov |
500 |
3.00 |
October 4, 2026 |
125 |
Nil |
Nil |
Nil |
(1) |
Each Option entitles the holder to purchase one Common Share. |
(2) |
As of December 31, 2024, the closing price of the Common Shares, was $3.25 per Common Share. |
Name
|
Option-based
awards – Value vested during the year
($)(1)
|
Share-based
awards – Value vested during the year ($) |
Non-equity
incentive plan compensation – Value earned during the year
($)
|
Oren Shuster |
1,821 |
Nil |
Nil |
Uri Birenberg |
Nil |
Nil |
Nil |
Richard Balla |
Nil |
Nil |
Nil |
Eyal Fisher |
14 |
Nil |
Nil |
Michal Lebovitz Nissimov |
42 |
Nil |
Nil |
(1) |
As of December 31, 2024, the closing price of the Common Shares was $3.25 per Common Share. |
Name(1)
|
Fees earned
($)(2) |
Share-based awards
($) |
Option-based awards ($)(3) |
Non-equity incentive
plan compensation ($) |
Pension value ($) |
All other compensation ($) |
Total
($) |
Brian Schinderle(4)
|
70,700 |
Nil |
4,015 |
Nil |
Nil |
Nil |
74,715 |
Moti Marcus(5)
|
80,200 |
Nil |
6,809 |
Nil |
Nil |
Nil |
87,009 |
Einat Zakariya(8)
|
74,200 |
Nil |
6,809 |
Nil |
Nil |
Nil |
81,009 |
Shmulik Arbel |
19,035 |
Nil |
Nil |
Nil |
Nil |
106,244(6)
|
125,279 |
Marc Lustig(7)
|
22,400 |
Nil |
Nil |
Nil |
Nil |
Nil |
22,400 |
(1) |
Each of Mr. Marcus Ms. Zakariya and Mr. Arbel received their compensation in NIS and Mr. Schinderle received his compensation in
USD. All salaries were converted to CDN pursuant to the average Bank of Canada rate for the applicable fiscal year. L5 Capital received
their fees in CDN. |
(2) |
Other than with respect to Mr. Lustig, each director was entitled to a $13,750 payment per quarter for their role as a director of
the Company. For each Audit Committee meeting, the Chair received a $1,500 payment and each other member received a $1,000 payment and
for each of the Compensation Committee and Governance and Nomination Committee meetings, the Chair received a $1,200 payment and each
other member received a $700 payment. |
(3) |
The Company used the Black-Scholes pricing model as the methodology to calculate the grant date fair value and relied on the following
key assumptions and estimates for each calculation under the following assumptions: (i) risk free interest rate of 3.23% (ii) expected
dividend yield of 0%; (iii) expected volatility of 128.1% to 137.34%; and (iv) a term of 2 years. The Black-Scholes pricing model was
used to estimate the fair value as it is the most accepted methodology. |
(4) |
Mr. Schinderle receives compensation through Solidum Capital Advisors LLC. |
(5) |
Mr. Marcus receives compensation through Marcus Management Services Ltd. |
(6) |
Mr. Arbel received additional compensation for his services as an adviser to the Company. This compensation was received in NIS and
converted to CDN pursuant to the average Bank of Canada rate for the applicable fiscal year. |
(7) |
Mr. Lustig resigned from his role as a director effective June 5, 2024. Mr. Lustig did not earn consideration for his role as a director
of the Company; however, Mr. Lustig, through L5 Capital, entered into a consulting agreement with the Company pursuant to which he was
paid $5,250 per month in consideration of his Executive Chairman services provided to the Company. Mr. Lustig resigned as Executive Chairman
effective June 5, 2024. |
Option-based
Awards |
Share-based
Awards | ||||||
Name
|
Number
of securities underlying unexercised Options (1)
(#)
|
Option
exercise price
($)
|
Option
expiration date |
Value
of
unexercised
in-the-money Options(2) ($)
|
Number
of shares or units of shares that have not vested
(#)
|
Market
or payout value of share-based awards that have not vested
($)
|
Market or payout value
of vested share-based awards not paid out or distributed
($) |
Brian Schinderle |
1,500 |
3.00 |
October 4, 2026 |
4,875 |
Nil |
Nil |
Nil |
Moti Marcus |
1,500 |
3.00 |
October 4, 2026 |
4,875 |
Nil |
Nil |
Nil |
Einat Zakariya |
1,500 |
3.00 |
October 4, 2026 |
4,875 |
Nil |
Nil |
Nil |
Shmulik Arbel |
Nil |
N/A |
N/A |
Nil |
Nil |
N/A |
N/A |
Marc Lustig |
Nil |
N/A |
N/A |
Nil |
Nil |
N/A |
N/A |
(1) |
Each Option entitles the holder to purchase one Common Share. |
(2) |
The closing price of the Common Shares as at December 31, 2024 was $3.25 per Common Share. |
Name
|
Option-based
awards – Value vested during the year(1)
($)
|
Share-based
awards – Value vested during the year ($) |
Non-equity
incentive plan compensation – Value earned during the year
($)
|
Brian Schinderle |
1,625 |
Nil |
Nil |
Moti Marcus |
1,625 |
Nil |
Nil |
Einat Zakariya |
1,625 |
Nil |
Nil |
(1) |
The closing price of the Common Shares as of December 31, 2024 was $3.25 per Common Share. |
Name of Director |
Board |
Audit Committee |
Compensation Committee |
Governance and Nomination Committee |
Oren Shuster |
14/14 |
N/A |
N/A |
N/A |
Marc Lustig(1)
|
7/14 |
N/A |
N/A |
N/A |
Moti Marcus |
14/14 |
6/6 |
1/1 |
N/A |
Einat Zakariya |
14/14 |
6/6 |
1/1 |
N/A |
Brian Schinderle |
14/14 |
6/6 |
1/1 |
N/A |
Shmulik Arbel(2)
|
2/14 |
N/A |
N/A |
N/A |
(1) |
Marc Lustig resigned as Executive Chairman and a director effective June 5, 2024. |
(2) |
Shmulik Arbel was appointed to the Board effective September 9, 2024. |
(a) |
overseeing that the day-to-day business affairs of the Company are appropriately managed and taking steps to maintain and enhance
an effective senior management team reporting to the CEO; |
(b) |
recommending to the Board the Company’s financial and operating goals and objectives and, following approval by the Board thereof,
consistently striving to achieve such goals and objectives; |
(c) |
formulating, and presenting to the Board for approval, long-term business plans, strategies and policies having the objective of
maximizing the Company’s long-term success and the creation of shareholder value; |
(d) |
together with other senior management, as are appropriate, developing and recommending to the Board annual business plans and budgets
that support the Company’s long term business plans and strategies; |
(e) |
developing and implementing, with senior management of the Company, plans, strategies, budgets and policies necessary to achieve
the goals and objectives of the Company; |
(f) |
supervising, maintaining and deploying the Company’s resources – human, financial or otherwise – with the purpose
and objective of achieving the Company’s operating goals and objectives; |
(g) |
keeping the Board informed in a timely and candid manner of the progress of the Company towards the achievement of its strategic
and operational goals and objectives and of all material deviations from the goals, objectives, plans, strategies, budgets or policies
established by the Board; |
(h) |
overseeing, evaluating and taking steps to enhance, where necessary, the integrity and reliability of the Company’s internal
controls, including its management information systems and financial reporting, and establishing, maintaining, designing and evaluating
disclosure controls and procedures for the Company; |
(i) |
identifying and managing business risks faced by the Company, including overseeing the design and implementation of appropriate systems
and procedures to effectively monitor, manage and mitigate such risks; |
(j) |
ensuring that the Board has regular exposure to the Company’s senior management and overseeing the development and succession
of the Company’s senior management team; |
(k) |
evaluating the performance of senior management of the Company and making recommendations with respect to their compensation;
|
(l) |
maintaining a positive and ethical work climate that is conducive to attracting, retaining and motivating a diverse group of top-quality
employees at all levels; |
(m) |
serving as the Company’s principal spokesperson and ensuring that information communicated to the public fairly portrays the
position of the Company and that timely and continuous disclosure obligations of the Company are met; |
(n) |
representing the Company in a such a way so as to enhance and maintain the Company’s reputation and to promote positive relationships
with shareholders, suppliers, contractors, clients, service providers, strategic partners, creditors, financial institutions, local communities,
all levels of government and the media; and |
(o) |
fulfilling all other responsibilities as assigned by the Board, in the manner expected by the Board. |
Name
|
Independence(1)
|
Financial
Literacy(2) |
Moti Marcus (Chair)
|
Independent
|
Financially literate
|
Brian Schinderle
|
Independent
|
Financially literate
|
Einat Zakariya
|
Independent
|
Financially literate
|
1. |
Within the meaning of subsection 1.4 of NI 52-110 and as determined under Exchange Act Rule 10A-3 and Rule 5605(a)(2) of the
Nasdaq Stock Market Rules. |
2. |
Within the meaning of subsection 1.6 of NI 52-110, Item 407(d)(5)(ii)-(iii) of Regulation S-K under the Exchange Act) and Rule 5605(c)(2)(A)
of the Nasdaq Stock Market Rules. |
(i) |
matters of governance; and |
(ii) |
the nomination of directors to the Board. |
1. |
Einat Zakariya (Chair); |
2. |
Oren Shuster; and |
3. |
Moti Marcus. |
Year |
Full Time |
Part Time |
Total | |||
Fiscal 2022 |
153 |
- |
153 | |||
Fiscal 2023 |
95 |
- |
95 | |||
Fiscal 2024 |
55 |
- |
55 |
Year |
Israel |
Germany |
Canada |
Total | ||||
Fiscal 2022 |
126 |
27 |
- |
153 | ||||
Fiscal 2023 |
77 |
18 |
- |
95 | ||||
Fiscal 2024 |
35 |
20 |
- |
55 |
• |
each person, or group of affiliated persons, known by us to beneficially own five percent (5%) or more of any class of our shares;
|
• |
each of our Named Executive Officers; |
• |
each of our directors; and |
• |
all of our directors and executive officers as a group. |
Name of Beneficial Holder
|
Number of Common Shares
Beneficially Held |
Number of Common Shares
Underlying Options |
Option Exercise Price ($) |
Option Expiration Date
|
Restricted Share Units
|
Debentures |
Warrants |
Total Convertible Securities
|
Percentage of Common
Shares Beneficially Held Undiluted |
Percentage of Common
Shares Beneficially Held Partially Diluted |
Oren Shuster(1)
|
616,831 |
21,875 |
3.00 |
October 4, 2026 |
Nil |
46,512 |
346,811 |
415,198(1)
|
19.9% |
33.45% |
Marc Lustig(2)
|
155,106 |
Nil |
Nil |
Nil |
Nil |
Nil |
105,643 |
105,643 |
5.02% |
8.45% |
Moti Marcus |
Nil |
1,500 |
3.00 |
October 4, 2026 |
Nil |
Nil |
Nil |
1,500 |
Nil |
0.04% |
Einat Zakariya |
10,200 |
1,500 |
3.00 |
October 4, 2026 |
Nil |
Nil |
Nil |
1,500 |
0.33% |
0.38% |
Brian Schinderle |
Nil |
1,500 |
3.00 |
October 4, 2026 |
Nil |
Nil |
Nil |
1,500 |
Nil |
0.04% |
Uri Birenberg |
Nil |
Nil |
N/A |
N/A |
Nil |
Nil |
Nil |
Nil |
Nil |
Nil |
Michal Lebovitz Nissimov |
Nil |
500 |
3.00 |
October 4, 2026 |
Nil |
Nil |
Nil |
500 |
Nil |
0.00% |
Richard Balla |
625 |
1,500 |
24 |
July 30, 2029 |
Nil |
Nil |
Nil |
1,500 |
0.00% |
0.00% |
Rafael Gabay(3)
|
389,707 |
1,500 |
3.00 |
October 4, 2026 |
Nil |
46,396 |
244,637 |
292,533 |
12.63% |
12.68% |
Shmulik Arbel |
54,859 |
Nil |
Nil |
Nil |
Nil |
Nil |
48,349 |
48,349 |
1.78% |
3.34% |
(1) |
616,806 Common Shares and 348,811 Warrants are held by Oren Shuster directly and 25 Common Shares are held indirectly through Ewave,
a privately-held entity of which Mr. Shuster owns and controls 50% of the outstanding voting rights. Mr. Shuster also holds 39,536 convertible
debentures. |
(2) |
50,065 Common Shares and 23,020 Warrants are held by Marc Lustig directly and 105,040 Common Shares and 82,624 Warrants are held
indirectly through L5 Capital, a privately held entity of which Mr. Lustig owns and controls 100% of the outstanding voting rights.
|
(3) |
389,682 Common Shares and 244,637 Warrants are held by Rafael Gabay directly and 25 Common Shares are held indirectly by Ewave, a
privately-held entity of which Mr. Gabay owns and controls 50% of the outstanding voting rights. Mr. Gabay also holds 46,396 convertible
debentures. |
• |
On April 2, 2019, IMC Holdings and Focus entered into an agreement (the "Focus Agreement")
pursuant to which IMC Holdings acquired an option to purchase, at its sole discretion and in compliance with Israeli cannabis regulation,
all of the ordinary shares held by Messrs. Shuster and Gabay held in Focus at a price equal to NIS 765.67 per ordinary share until April
2029. On November 30, 2023, IMC Holdings sent a request letter to IMCA to approve IMC Holding’s exercise of the option and on February
26, 2024, IMCA's approval was obtained. Effective February 26, 2024, IMC Holdings acquired 74% of the ordinary shares of Focus.
|
• |
The Company is a party to indemnification agreements with certain directors and officers of the Company and Trichome to cover certain
tax liabilities, interest and penalties arising from the Company’s acquisition of all of issued and outstanding securities of Trichome
and certain of its subsidiaries. |
• |
On August 5, 2022, the Company sold Sublime to a group of purchasers that included current and former members of the Sublime management
team for aggregate proceeds of $100,000 less working capital adjustments, for a final net purchase price of $89,000. The transaction constituted
a “related party transaction” within the meaning of MI 61-101, however pursuant to Sections 5.5(a) and 5.7(1)(a) of MI 61-101,
the transaction was exempt from the formal valuation and minority shareholder approval requirements of such instrument. |
• |
On August 19, 2022, the Company announced a non-brokered private placement offering of Common Shares (the “2022
Private Placement”) for aggregate gross proceeds of up to US$5,000 led by the Company’s management and executive team.
The first and second tranche of which closed on August 24, 2022, and October 5, 2022, respectively. Insiders of the Company, led by the
CEO and Director, and the Company’s former CFO, subscribed for 1,563,496 Common Shares for aggregate proceeds of US$782 in the first
tranche of the 2022 Private Placement, and the Executive Chairman of the Company, subscribed for 1,112,504 Common Shares for aggregate
proceeds of US$556 in the second tranche of the 2022 Private Placement. As a result of the participation by the CEO, CFO and Executive
Chairman, the 2022 Private Placement was considered a “related party transaction” pursuant to MI 61-101. The Company relied
on Sections 5.5(a) and 5.7(1)(a) of MI 61-101 for exemptions from the requirements to obtain a formal valuation and minority shareholder
approval, respectively, because the fair market value of the insiders’ participation in the 2022 Private Placement was below 25%
of the Company’s market capitalization for purposes of MI 61-101. |
• |
The Stalking Horse Purchase Agreement constituted a related party transaction as L5 Capital is an entity controlled by Marc Lustig,
who was a director of Trichome and the Executive Chairman of the Board. On March 8, 2023, the Company announced that the SISP approved
by the Court did not result in any bids for the going-concern business of Trichome; however, L5 Capital advised that it would not complete
the proposed transaction contemplated by the Stalking Horse Share Purchase Agreement. |
• |
On January 16, 2023, the Company closed of the first tranche of the LIFE Concurrent Offering comprised of an aggregate of 1,159,999
Units for aggregate gross proceeds of US$1,500. The LIFE Concurrent Offering was led by insiders of the Company. The units offered under
the LIFE Concurrent Offering were sold under similar terms as the Life Offering. |
• |
On January 20, 2023, the Company closed the second tranche of the LIFE Offering comprised of 102,152 Life Units for an aggregate
subscription price of approximately US$128. The second tranche of the LIFE Offering was comprised of a single subscription by the Executive
Chairman of the Company whose subscription price was satisfied by the settlement of approximately US$128 in debt owed by the Company to
him for certain consulting services previously rendered to the Company. |
• |
On February 16, 2023, the Company closed the fifth and final tranche of the LIFE Offering. Marc Lustig, the Executive Chairman of
the Company subscribed for 29,548 Life Units in the fifth tranche at an aggregate subscription price of US$37. Marc Lustig’s subscription
price was satisfied by the settlement of US$37 in debt owed by the Company to the director for certain consulting services previously
rendered by the director to the Company. The participation by Company’s insiders in each of the LIFE Concurrent Offering and LIFE
Offering constituted “related party transactions” pursuant to MI 61-101. The Company relied on Sections 5.5(a) and 5.7(1)(a)
of MI 61-101 for exemptions from the requirements to obtain a formal valuation and minority shareholder approval, respectively, because
the fair market value of the insiders’ participation in the LIFE Concurrent Offering and LIFE Offering, as applicable, was below
25% of the Company’s market capitalization for the purposes of MI 61-101. |
• |
Pursuant to the consulting agreement between the Company and L5 Capital, the Company issued 50,414 Common Shares as a result of the
vested RSUs according to the agreed vesting schedule. The Common Shares were issued on May 5, 2023. On July 24, 2023, an additional 4,585
Common Shares were issued as a result of the vested RSUs according to the agreed vesting schedule. |
• |
On October 12, 2023, Oren Shuster, the CEO, loaned an amount of NIS 500 (approximately $170) to IMC Holdings. The participation of
the Mr. Shuster constituted a “related party transaction”, as such term is defined in MI 61-101 and would require the Company
to receive minority shareholder approval for and obtain a formal valuation for the subject matter of, the transaction in accordance with
MI 61-101, prior to the completion of such transaction. However, in completing the loan, the Company has relied on exemptions from the
formal valuation and minority shareholder approval requirements of MI 61-101, in each case on the basis that the fair market value of
the CEO’s loan did not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101.
|
• |
On May 29, 2024, Mr. Shuster subscribed for an aggregate of $237,214 of May 2024 Debentures in the May 2024 Private Placement. Mr.
Shuster’s participation in the May 2024 Private Placement is a “related party transaction”. For more information, see
“Item 4B. Business Overview – Important Events in the Development of the Business in Fiscal
2024 to the date of this Annual Report”. |
• |
Mr. Oren Shuster, Mr. Shmulik Arbel, and Mr. Rafael Gabay, each participated in the November 2024 Offering. Mr. Shuster acquired
194,109,110 November 2024 Units, 110,576 Common Shares in connection with the November 2024 Debt Settlement, and 122,141152,701 Pre-Funded
November 2024 Warrants. Mr. Arbel acquired 48,348 Nov 2024 Units, and Mr. Gabay acquired 194,087 Nov 2024 Units. For more information,
see “Item 4B. Business Overview – Important Events in the Development of the Business in
Fiscal 2024 to the date of this Annual Report”. |
•
|
Effective October 4, 2024, the Company cancelled the October 2024 Cancelled Options,
which were previously granted to board members, officers, employees, advisors and consultants of the Issuer. For more information, see
“Item 4B. Business Overview – Important Events in the Development of the Business in Fiscal
2024 to the date of this Annual Report”. |
•
|
Effective October 4, 2024, the Company cancelled an aggregate of 142,784 October 2024
Subject Warrants to purchase Shares, which were previously granted to Mr. Shuster. Management reviewed the Company’s outstanding
warrants and determined that the October 2024 Subject Warrants at an exercise price of US$9.00 per Share, no longer represented a realistic
incentive to motivate Mr. Shuster. For more information, see “Item 4B. Business Overview –
Important Events in the Development of the Business in Fiscal 2024 to the date of this Annual Report”. |
•
|
On November 12, 2024, the Company completed a debt settlement (the “November
2024 Debt Settlement”) in the amount of US$560,000 with Mr. Shuster. Since October 2022, the Company, through its subsidiaries,
had borrowed more than US$8,000,000 (together, the “Loans”) from various groups. As
required by the lenders, Mr. Shuster, the Company's CEO and chairman of the Board personally guaranteed the Loans. The independent members
of the Board commissioned a valuation to determine the value of Mr. Shuster’s personal guarantees, which ascribes the benefit to
the Company to be approximately US$560,000 (the “Shuster Benefit”). To repay Mr. Shuster
in connection with the Shuster Benefit, and to preserve the Company’s cash for working capital, the issued Mr. Shuster 110,576 Common
Shares and 152,701 pre-funded Common Share purchase warrants (each, a “Pre-Funded November 2024
Warrant”) at a deemed price of C$2.88 For more information, see “Item 4B. Business Overview – Important Events
in the Development of the Business in Fiscal 2024 to the date of this Annual Report”. |
1. |
The contractual party of the company was not Stroakmont. The contract with Stroakmont was only concluded as a sham transaction to
cover up a contract with a company named Uniclaro GmbH (“Uniclaro”). Therefore, Stroakmont
is not the real purchaser rather than Uniclaro. |
2. |
The company allegedly placed an order with Uniclaro for a total of 4.3 million Clongene COVID-19 tests, of which Uniclaro claims
to have a payment claim against the company for a partial delivery of 380,400 Clongene COVID-19 tests in the total amount of EUR 942.
Uniclaro has assigned this alleged claim against the company to Stroakmont Trading GmbH, and Stroakmont Trading GmbH has precautionary
declared a set-off against the company’s claim. |
1. |
Adjupharm was not sentenced. Uniclaro's lawsuit for payment of approximately EUR 1,046
thousand in exchange for delivery of 300,000 Clungene tests was dismissed. |
2. |
Uniclaro is sentenced to pay Adjupharm approximately EUR 54 thousand plus interest
at 5 percentage points above the German basis rate since January 17, 2023. |
3. |
Uniclaro shall bear the procedural costs. |
1. |
under the age of 18 years; |
2. |
found by a court, in Canada or elsewhere, to be incapable of managing the individual’s own affairs, unless a court, in Canada
or elsewhere, subsequently finds otherwise; |
3. |
an undischarged bankrupt; or |
4. |
convicted in or out of the Province of British Columbia of an offence in connection with the promotion, formation or management of
a corporation or unincorporated business, or of an offence involving fraud, unless: |
a. |
the court orders otherwise; |
b. |
5 years have elapsed since the last to occur of: |
i. |
the expiration of the period set for suspension of the passing of sentence without a sentence having been passed; |
ii. |
the imposition of a fine; |
iii. |
the conclusion of the term of any imprisonment; and |
iv. |
the conclusion of the term of any probation imposed; or |
c. |
a pardon was granted or issued, or a record suspension ordered, under the Criminal Records Act (Canada) and the pardon or record
suspension, as the case may be, has not been revoked or ceased to have effect. |
a. |
Focus IP Agreement and the Cancellation Note. |
b. |
Focus Option Agreement. For more information, please see “Item 4B. Business Overview –
Economic Dependence”. |
c. |
Service Agreement with Focus. |
d. |
The Kadimastem Loan Agreement. |
e. |
Telecana Loan Agreement. For more information, please see “Item 4A. History and Development of the
Company – Important Events in the Development of the Business in Fiscal 2024 to the date of this
Annual Report”. |
• |
an individual who is a citizen or resident of the United States; |
• |
a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United
States, any state thereof or the District of Columbia; |
• |
an estate whose income is subject to U.S. federal income taxation regardless of its source; or |
• |
a trust that (i) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons
for all substantial decisions or (ii) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.
|
• |
at least 25% of the issued shares of any class or series of our capital stock was owned by or belonged to any combination of
(a) the Non-Canadian Holder, (b) persons with whom the Non-Canadian Holder does not deal at arm’s length for purposes of the Canadian
Tax Act, and (c) partnerships in which the Non-Canadian Holder or a person described in (b) holds a membership interest directly or indirectly
through one or more partnerships, and |
• |
more than 50% of the fair market value of the Common Shares was derived, directly or indirectly, from one or any combination of:
(i) real or immoveable property situated in Canada, (ii) “Canadian resource properties” (as that term is defined in the Canadian
Tax Act), (iii) “timber resource properties” (as that term is defined in the Canadian Tax Act) or (iv) options in respect
of, or interests in, or for civil law rights in, a property described in any of the foregoing whether or not the property exists.
|
2024 |
2023 | |
Audit Fees |
$281 |
$297 |
Audit-related Fees(1)
|
$- |
$28 |
Tax Fees(2)(3)
|
$44 |
$68 |
All Other Fees(4)
|
$29 |
$13 |
Total |
$354 |
$406 |
1. |
Consists of fees for professional services and expenses relating to the audit of the annual financial statements and review of our
quarterly financial information. Fees charged for assurance and related services reasonably related to the performance of an audit, and
not included under “Audit Fees”. |
2. |
Consists of fees for professional services and expenses reasonably relating to the audit of the annual financial statements or review
of our quarterly financial information and are not reported as “Audit Fees”. Fees charged for tax compliance, tax advice and
tax planning services. |
3. |
Consists of fees for tax-related services related primarily to tax consulting and tax planning. |
4. |
Fees for services other than disclosed in any other row, including fees related to the review of management’s discussion and
analysis and Sarbanes-Oxley Act procedures. |
• |
an Information Security Policy that articulates our information security practices and procedures to maintain confidence in our business and to protect the confidentiality, integrity, and availability of the information we handle;
|
• |
a dedicated Cyber Security company responsible for executing on relevant internal and external requirements and identifying appropriate technical and organizational measures to deliver information security in compliance with those requirements;
|
• |
a Cyber Security company, principally responsible for driving our cybersecurity risk assessment processes, including a formal information security risk assessment on an at least annual basis; our security controls framework and risk remediation and prioritizations; and risk awareness or education programs for employees relating to cybersecurity;
|
• |
the use of external resources, such as assessors, consultants, and auditors, where appropriate, to assess, test, or otherwise assist with aspects of our security controls;
|
• |
an external audit of our systems and environments, including an external penetration test, on an annual basis;
|
• |
cybersecurity training of our incident response personnel and senior management;
|
• |
a cybersecurity incident response plan that includes procedures for assessing, responding to, remediating, resolving, and conducting post-analysis of cybersecurity incidents;
|
• |
|
• |
contractual obligations on third-party vendors to report security incidents, risk identification, or other security-related issues promptly to designated contact personnel at the Company.
|
Consolidated Financial Statements for the Years Ended December 31, 2024 and 2023
|
Independent Auditors’ Reports
|
Consolidated Statements of Financial Position
|
Consolidated Statements of Net Loss and Comprehensive Loss
|
Consolidated Statements of Changes in Shareholders’ Equity
|
Consolidated Statements of Cash Flows
|
Notes to the Consolidated Financial Statements
|
Description
|
Page
|
|
F-1 - F-69
|
Exhibit
|
|
No.
|
Description of Exhibit
|
4.8* | |
101.INS*
|
XBRL Instant Document
|
101.SCH*
|
XBRL Taxonomy Extension Schema Document
|
101.CAL*
|
XBLR Taxonomy Extension Calculation Linkbase Document
|
101.DEF*
|
XBRL Taxonomy Extension Definition Linkbase
|
101.LAB*
|
XBRL Taxonomy Extension Label Linkbase
|
101.PRE*
|
XBRL Taxonomy Extension Presentation Linkbase
|
104*
|
Cover Page Interactive Data File – (formatted as Inline XBRL and contained in Exhibit 101)
|
IM Cannabis Corp. | |||
Date: March 31, 2025
|
By:
|
/s/ Oren Shuster | |
Name: Oren Shuster | |||
Title: Chief Executive Officer and Chairman of the Board |
|
Page |
Report of Independent Registered Public Accounting Firm (PCAOB ID: 1375)
|
F-2
|
Report of Independent Registered Public Accounting Firm (PCAOB ID:
|
F-3
|
F-4 - F-5
|
|
F-6 - F-7
|
|
F-8 - F-10
|
|
F-11 - F-12
|
|
F-13 - F-69
|
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
Fahn Kanne & Co.
Head Office
32 Hamasger Street
Tel-Aviv 6721118, ISRAEL
PO Box 36172, 6136101
T +972 3 7106666
F +972 3 7106660
www.gtfk.co.il
|
Board of Directors and Shareholders
IM Cannabis Corp.
|
|
|
![]() |
Kost Forer Gabbay & Kasierer
144 Menachem Begin Road, Building A,
Tel-Aviv 6492102, Israel
|
Tel: +972-3-6232525
Fax: +972-3-5622555
ey.com
|
/s/
|
KOST
FORER GABBAY & KASIERER
A
Member of Ernst & Young Global
|
We have served as the Company's auditor from 2018 to 2025.
|
|
March 28, 2024
|
December 31,
|
||||||||||||
Note
|
2024
|
2023
|
||||||||||
ASSETS
|
||||||||||||
CURRENT ASSETS:
|
||||||||||||
Cash
|
$
|
|
$
|
|
||||||||
Restricted cash deposit
|
|
|
||||||||||
Trade receivables
|
5
|
|
|
|||||||||
Other current assets
|
6
|
|
|
|||||||||
Inventory
|
7
|
|
|
|||||||||
|
|
|||||||||||
NON-CURRENT ASSETS:
|
||||||||||||
Investments in affiliate
|
8
|
|
|
|||||||||
Property, plant and equipment, net
|
9
|
|
|
|||||||||
Intangible assets, net
|
10
|
|
|
|||||||||
Goodwill
|
10
|
|
|
|||||||||
Right-of-use assets, net
|
11
|
|
|
|||||||||
|
|
|||||||||||
Total assets
|
$
|
|
$
|
|
December 31,
|
|||||||||||
Note
|
2024
|
2023
|
|||||||||
LIABILITIES AND SHAREHOLDERS' EQUITY
|
|||||||||||
CURRENT LIABILITIES:
|
|||||||||||
Current maturities of operating lease liabilities
|
11
|
$
|
|
$
|
|
||||||
Trade payables
|
12
|
|
|
||||||||
Other current liabilities
|
13
|
|
|
||||||||
Credit from bank institutions and others
|
14
|
|
|
||||||||
Convertible debentures
|
15
|
|
|
||||||||
Derivative warrants liabilities and prefunded warrants
|
16
|
|
(*) |
|
|||||||
Accrued purchase consideration liability
|
19F
|
|
|
||||||||
Put option liability
|
19F
|
|
|
||||||||
|
|
||||||||||
NON-CURRENT LIABILITIES:
|
|||||||||||
Operating lease liabilities
|
11
|
|
|
||||||||
Credit from bank institutions and others
|
14
|
|
|
||||||||
Employee benefit liabilities, net
|
|
|
|||||||||
Deferred tax liabilities
|
|
|
|||||||||
|
|
||||||||||
Total liabilities
|
|
|
|||||||||
CONTINGENT LIABILITIES
|
17
|
||||||||||
EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY:
|
18
|
||||||||||
Share capital and premium
|
|
|
|||||||||
Capital reserve from translation differences of foreign operations
|
(
|
)
|
|
||||||||
Conversion feature related to convertible debentures
|
15
|
|
|
||||||||
Capital reserve from share-based payment transactions
|
|
|
|||||||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
|||||||
Total equity attributable to shareholders of the Company
|
|
|
|||||||||
Non-controlling interests
|
(
|
)
|
(
|
)
|
|||||||
Total shareholders' equity
|
|
|
|||||||||
Total shareholders' equity and liabilities
|
$
|
|
$
|
|
March 31, 2025
|
/s/ Oren Shuster |
/s/ Moti Marcus
|
/s/ Uri Birenberg | |||
Date of approval of the
|
Oren Shuster
|
Moti Marcus
|
Uri Birenberg
|
|||
financial statements
|
Chief Executive Officer and Chairman of the Board
|
Chairman of the Audit Committee
|
Chief Financial Officer
|
IM CANNABIS CORP. AND ITS SUBSIDIARIES
Year ended
December 31,
|
||||||||||||||||
Note
|
2024
|
2023
|
2022
|
|||||||||||||
Revenue
|
19A
|
$
|
|
$
|
|
$
|
|
|||||||||
Cost of revenue
|
19B
|
|
|
|
||||||||||||
Gross profit before fair value adjustments
|
|
|
|
|||||||||||||
Fair value adjustments:
|
||||||||||||||||
Unrealized change in fair value of biological assets
|
|
|
(
|
)
|
||||||||||||
Realized fair value adjustments on inventory sold or impaired
|
|
(
|
)
|
(
|
)
|
|||||||||||
Total fair value adjustments
|
|
(
|
)
|
(
|
)
|
|||||||||||
Gross profit after fair value adjustments
|
|
|
|
|||||||||||||
Selling and marketing expenses
|
19C
|
|
|
|
||||||||||||
General and administrative expenses
|
19D
|
|
|
|
||||||||||||
Restructuring expenses
|
19E
|
|
|
|
||||||||||||
Other expenses
|
19F
|
|
|
|
||||||||||||
Share-based compensation
|
18C
|
|
|
|
||||||||||||
Total operating expenses
|
|
|
|
|||||||||||||
Operating loss
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Finance income
|
|
|
|
|||||||||||||
Finance expenses
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Finance income (expense), net
|
(
|
)
|
|
|
||||||||||||
Loss before taxes on income (tax benefit)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Taxes on income (tax benefit)
|
20
|
(
|
)
|
|
(
|
)
|
||||||||||
Net loss from continuing operations
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Net loss from discontinued operations, net of tax
|
21
|
|
|
(
|
)
|
|||||||||||
Net loss
|
(
|
)
|
(
|
)
|
(
|
)
|
IM CANNABIS CORP. AND ITS SUBSIDIARIES
Year ended
December 31,
|
||||||||||||||||
Note
|
2024
|
2023 (*)
|
|
2022 (*)
|
|
|||||||||||
Other comprehensive income (loss) that will not be reclassified to profit or loss in subsequent periods:
|
||||||||||||||||
Remeasurement gain on defined benefit plans
|
|
|
|
|||||||||||||
Total other comprehensive income (loss) that will not be reclassified to profit or loss in subsequent periods
|
|
|
|
|||||||||||||
Other comprehensive income (loss) that will be reclassified to profit or loss in subsequent periods:
|
||||||||||||||||
Adjustments arising from translation of financial statements of foreign operations
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Total other comprehensive loss
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Total comprehensive loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||
Net loss attributable to:
|
||||||||||||||||
Shareholders of the Company
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||
Non-controlling interests
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||
Total comprehensive loss attributable to:
|
||||||||||||||||
Shareholders of the Company
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||
Non-controlling interests
|
$
|
(
|
)
|
$
|
(
|
)
|
(
|
)
|
||||||||
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||
Loss per share attributable to shareholders of the Company from continuing operations:
|
22
|
|||||||||||||||
Basic loss per share (in CAD)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||
Diluted loss per share (in CAD)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||
Loss per share attributable to shareholders of the Company from discontinued operations:
|
||||||||||||||||
Basic and diluted loss per share (in CAD)
|
|
|
$
|
(
|
)
|
|||||||||||
Loss per share attributable to shareholders of the Company from net loss:
|
||||||||||||||||
Basic loss per share (in CAD)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||
Diluted loss per share (in CAD)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
(*) |
Loss per share includes the effect of Reverse Share Split (see also Note 18A below).
|
The accompanying notes are an integral part of the consolidated financial statements.
IM CANNABIS CORP. AND ITS SUBSIDIARIES
Share capital and premium
|
Treasury shares
|
Capital reserve from share-based payment transactions
|
Capital reserve from translation difference of foreign operations
|
Accumulated deficit
|
Total
|
Non-controlling interests
|
Total
Shareholders' equity
|
|||||||||||||||||||||||||
Balance as of January 1, 2022
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
||||||||||||||
Net loss
|
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||
Total other comprehensive income (loss)
|
|
|
|
(
|
)
|
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||
Total comprehensive loss
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
Common shares issued as settlement of purchase consideration through business combination transactions (Notes 18B1-18B3)
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Issuance of treasury common shares
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Common shares issued through private placements transactions, net of issuance costs (Note 18B4)
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Common shares issued upon options exercised (Note 18B9)
|
|
|
(
|
)
|
|
|
|
|
|
|||||||||||||||||||||||
Share-based compensation
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Expired options
|
|
|
(
|
)
|
|
|
|
|
|
|||||||||||||||||||||||
Balance as of December 31, 2022
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
IM CANNABIS CORP. AND ITS SUBSIDIARIES
Share capital and premium
|
Capital reserve from share-based payment transactions
|
Capital reserve from translation difference of foreign operations
|
Accumulated deficit
|
Total
|
Non-controlling interests
|
Total
Shareholders' equity
|
||||||||||||||||||||||
Balance as of January 1, 2023
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
|||||||||||||
Net loss
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||||||||||||
Total other comprehensive income (loss)
|
|
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||||
Total comprehensive loss
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||
Common shares issued through private placements transactions, net of issuance costs (Note 18B5)
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Common shares issued as debts settlement with related party (Note 18B6)
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Other comprehensive loss classification
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||||||||||||
Share-based compensation
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Expired options
|
|
(
|
)
|
|
|
|
|
|
||||||||||||||||||||
Balance as of December 31, 2023
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
|
IM CANNABIS CORP. AND ITS SUBSIDIARIES
Share capital and premium
|
Capital reserve from share-based payment transactions
|
Conversion option for convertible debt
|
Capital reserve from translation difference of foreign operations
|
Accumulated deficit
|
Total
|
Non-controlling interests
|
Total
Shareholders' equity
|
|||||||||||||||||||||||||
Balance as of January 1, 2024
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
|
||||||||||||||
Net loss
|
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||
Total other comprehensive income (loss)
|
|
|
|
(
|
)
|
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||
Total comprehensive loss
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
Common shares issued through private placement transaction, net of issuance costs (Note 18B7)
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Common shares issued as share-based compensation with related party (Note 18B8)
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Recognition of conversion feature related to convertible debentures (Note 15)
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Other comprehensive loss classification
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Share-based compensation
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Expired and exercised options
|
|
(
|
)
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance as of December 31, 2024
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
|
IM CANNABIS CORP. AND ITS SUBSIDIARIES
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Cash flows used in operating activities:
|
||||||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Adjustments for non-cash items:
|
||||||||||||
Unrealized gain on changes in fair value of biological assets
|
|
|
(
|
)
|
||||||||
Realized fair value adjustments on inventory sold or impaired
|
|
|
|
|||||||||
Revaluation of financial instruments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Issuance costs allocated to warrants granted |
||||||||||||
Disposal of property, plant and equipment |
||||||||||||
Common shares and prefunded warrants issued as share-based compensation with related party
|
|
|
|
|||||||||
Discount expenses in respect of convertible debentures
|
|
|
|
|||||||||
Depreciation of property, plant and equipment
|
|
|
|
|||||||||
Amortization of intangible assets
|
|
|
|
|||||||||
Depreciation of right of use assets
|
|
|
|
|||||||||
Impairment of goodwill
|
|
|
|
|||||||||
Impairment of property, plant and equipment
|
|
|
|
|||||||||
Impairment of intangible assets
|
|
|
|
|||||||||
Impairment of right of use assets
|
|
|
|
|||||||||
Finance income, net
|
|
|
|
|||||||||
Deferred tax payments (benefit), net
|
(
|
)
|
|
(
|
)
|
|||||||
Share-based payments
|
|
|
|
|||||||||
Revaluation of other current receivable
|
|
|
|
|||||||||
Loss from deconsolidation of Oranim
|
|
|
|
|||||||||
Restructuring expenses
|
|
|
|
|||||||||
Revaluation expenses of investment in affiliate
|
|
|
|
|||||||||
Revaluation expenses (income) of loans receivables
|
(
|
)
|
|
|
||||||||
Changes in employee benefit liabilities, net
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Gain from debts restructuring
|
(
|
)
|
|
|
||||||||
Discount expenses in respect of credit
|
|
|
|
|||||||||
|
|
|
||||||||||
Changes in non-cash working capital:
|
||||||||||||
Increase (decrease) in trade receivables
|
(
|
)
|
|
|
||||||||
Increase in other current assets
|
|
|
|
|||||||||
Decrease in biological assets, net of fair value adjustments
|
|
|
|
|||||||||
Increase in inventory, net of fair value adjustments
|
|
|
|
|||||||||
Increase (decrease) in trade payables
|
|
(
|
)
|
|
||||||||
Increase (decrease) in other current liabilities
|
(
|
)
|
(
|
)
|
|
|||||||
|
|
|
||||||||||
Taxes paid
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net cash used in operating activities
|
(
|
)
|
(
|
)
|
(
|
)
|
IM CANNABIS CORP. AND ITS SUBSIDIARIES
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Cash flows used in investing activities:
|
||||||||||||
Purchase of property, plant and equipment
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds from sales of property, plant and equipment
|
|
|
|
|||||||||
Proceeds from loans receivable
|
|
|
|
|||||||||
Deconsolidation of subsidiary
|
(
|
)
|
|
(
|
)
|
|||||||
Investments in affiliate
|
|
|
(
|
)
|
||||||||
Loan granted
|
|
(
|
)
|
|
||||||||
Change in restricted cash
|
(
|
)
|
|
|
||||||||
Net cash used in investing activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Cash provided by financing activities:
|
||||||||||||
Proceeds allocated to issuance of share capital, net of issuance costs |
|
|
|
|||||||||
Proceeds allocated to issuance of warrants measured at fair value, net of issuance costs |
|
|
|
|||||||||
Proceeds received from common shares issued upon options exercised
|
|
|
|
|||||||||
Repayment of lease liabilities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Payment of interest on lease liabilities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds from loans received
|
|
|
|
|||||||||
Repayment of loans
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Interest paid
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds received from discounted checks
|
|
|
|
|||||||||
Net cash provided by financing activities
|
|
|
|
|||||||||
Effect of foreign exchange on cash
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Change in cash
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Cash at the beginning of year
|
|
|
|
|||||||||
Cash at the end of year
|
$
|
|
$
|
|
$
|
|
||||||
Supplemental disclosure of non-cash activities:
|
||||||||||||
Right of use assets recognized with corresponding lease liabilities
|
$
|
|
$
|
|
$
|
|
||||||
Common shares issued as settlement of purchase consideration through business combination transactions
|
$
|
|
$
|
|
$
|
|
||||||
Common shares and prefunded warrants issued as debts settlement with related party
|
$
|
|
$
|
|
$
|
|
||||||
Common shares and warrants issued as debts settlement with related party
|
$
|
|
$
|
|
$
|
|
||||||
Issuance of convertible debentures in exchange for loans (principal and interest) received
|
$
|
|
$
|
|
$
|
|
||||||
Revaluation of put option liability versus equity
|
$
|
|
$
|
|
$
|
|
IM CANNABIS CORP. AND ITS SUBSIDIARIES
NOTE 1 - |
GENERAL
|
A. |
Corporate information
|
NOTE 1 - |
GENERAL (Cont.)
|
B. |
Liquidity and capital resources and going concern
|
C. |
Impact of continued interest rate on the Group's business activity
|
NOTE 1 - |
GENERAL (Cont.)
|
D. |
Impact of the 'Iron Swords' war on the Group's business activity
|
NOTE 2 - |
BASIS OF PRESENTATION
|
A. |
Statement of Compliance
|
B. |
Basis of Measurement
|
C. |
Use of Significant Accounting Estimates and Assumptions and Judgements
|
D. |
The Functional Currency and the Presentation Currency
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES
|
A. |
Consolidated financial statements
|
Percentage ownership
|
||||||||
Subsidiaries
|
2024
|
2023
|
||||||
I.M.C. Holdings Ltd.
|
|
%
|
|
%
|
||||
Focus Medical Herbs Ltd. (*)
|
|
%
|
|
%
|
||||
I.M.C. Farms Israel Ltd. (****)
|
|
% |
|
% | ||||
Oranim Plus Pharm Ltd. (**)
|
|
%
|
|
%
|
||||
Oranim Pharm (**)
|
|
%
|
|
%
|
||||
IM Cannabis Holding NL B.V (***)
|
|
%
|
|
%
|
||||
Adjupharm GmbH
|
|
%
|
|
%
|
||||
I.M.C. Pharma Ltd.
|
|
%
|
|
%
|
||||
I.M.C.C. Medical Herbs Ltd. (*****)
|
|
%
|
|
%
|
||||
R.A. Yarok Pharm Ltd.
|
|
%
|
|
%
|
||||
Rosen High Way Ltd.
|
|
%
|
|
%
|
||||
Revoly Trading and Marketing Ltd.
|
|
%
|
|
%
|
(*) |
IMC Holdings held an option to acquire from main shareholders of the company an ownership which represents a rate of
|
(**) |
Was deconsolidated effective April 15, 2024 (see also Note 19F below).
|
(***) |
Inactive entity.
|
(****) |
On January 8, 2025, the Israeli Companies Registrar approved the liquidation status which shall be completed 100 days from the approval date.
|
(*****) |
On January 13, 2025, the Israeli Companies Registrar approved the liquidation status which shall be completed 100 days from the approval date.
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
B. |
Business combinations and goodwill
|
C. |
Cash
|
D. |
Inventories
|
◾ |
Raw materials - at cost of purchase using the "first-in, first-out" method.
|
◾ |
Work in progress and finished goods - on the basis of average costs including materials, labor and other direct and indirect manufacturing costs based on normal capacity.
|
◾ |
Purchased merchandise and products - using the weighted average cost method or using the "first-in, first-out" method.
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
E. |
Revenue recognition
|
◾ |
The reason for the bill-and-hold arrangement is substantive (for example, the customer has requested the arrangement);
|
◾ |
The product is identified separately as belonging to the customer;
|
◾ |
The product currently is ready for physical delivery to the customer;
|
◾ |
The Group does not have the ability to use the product by selling it or delivering it to another customer.
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
F. |
Taxes on income
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
G. |
Non-current assets or disposal group held for sale and discontinued operations
|
H. |
Post-employment benefits
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
I. |
Leases
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
J. |
Property, plant and equipment, net
|
%
|
||
Building
|
|
|
Equipment and furniture
|
|
|
Vehicles
|
|
|
Computer, software and equipment
|
|
|
Leasehold improvements
|
( )
|
(*) |
Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term and the useful life of the improvement.
|
K. |
Intangible assets, net
|
Years
|
||
Cultivations and processing licenses
|
( )
|
|
Customer relationships
|
|
|
Trade name
|
|
(*) |
The licenses consist of GMP and GDP licenses in Germany which have determined to have an indefinite useful life.
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
L. |
Impairment of non-financial assets
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
M. |
Financial instruments
|
1. |
Financial assets:
|
- |
The Group’s business model for managing financial assets; and
|
- |
The contractual cash flow terms of the financial asset.
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
L. |
Financial instruments (Cont.)
|
2. |
Financial liabilities:
|
N. |
Fair value measurement
|
Level 1
|
-
|
quoted prices (unadjusted) in active markets for identical assets or liabilities.
|
Level 2
|
-
|
inputs other than quoted prices included within Level 1 that are observable directly or indirectly.
|
Level 3
|
-
|
inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
O. |
Provisions
|
P. |
Issuance of a unit of securities
|
Q. |
Convertible debentures
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
R. |
Put option granted to non-controlling interests
|
S. |
Share-based payment transactions
|
T. |
Loss per share
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
U. |
Treasury shares
|
V. |
Operating cycle
|
W. |
New standards, amendments and interpretations to existing standards that are effective and relevant to the Group's business activity
|
1. |
Amendments to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current
|
2. |
Amendments to International Accounting Standard 7, Cash Flow Report, and International Financial Reporting Standard 7, Financial Instruments: Disclosures
|
NOTE 3 - |
MATERIAL ACCOUNTING POLICIES (Cont.)
|
X. |
Disclosure of new standards in the period prior to their adoption
|
1. |
IFRS 18, Presentation and Disclosure in Financial Statements
|
◾ |
IFRS 18 changes the structure of the profit or loss report and includes three new defined categories: operating, investment and financing and adds two new interim summaries: operating profit and profit before financing and income taxes.
|
◾ |
IFRS 18 includes guidelines for providing disclosure on performance indicators defined by management (Management-defined performance measures).
|
◾ |
IFRS 18 provides guidelines regarding the aggregation and disaggregation of the information in the financial statements in relation to the question of whether information should be included in the main reports or in explanations and disclosures regarding items defined as "other".
|
◾ |
IFRS 18 includes amendments to other standards, including limited amendments to International Accounting Standard 7, Statement of Cash Flows.
|
2. |
Amendments to IAS 21, "The Effects of Changes in Foreign Exchange Rates"
|
NOTE 4 - |
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS
|
A. |
Judgments:
|
- |
Determining the fair value of share-based payment transactions and similar instruments:
|
- |
Discount rate for lease liability:
|
B. |
Estimates and assumptions:
|
- |
Impairment of inventory:
|
- |
Determining the fair value of unquoted financial assets:
|
NOTE 4 - |
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS (Cont.)
|
C. |
Estimates and assumptions (Cont.):
|
- |
Impairment of goodwill:
|
- |
Legal claims:
|
- |
Deferred tax assets:
|
NOTE 5 - |
TRADE RECEIVABLES
|
NOTE 6 - |
OTHER ACCOUNTS ASSETS
|
December 31,
|
||||||||
2024
|
2023
|
|||||||
Prepaid expenses
|
$
|
|
$
|
|
||||
Advances to suppliers
|
|
|
||||||
Government authorities
|
|
|
||||||
Former non-independent director (see Note 24A below)
|
|
|
||||||
Shareholders (see Note 24A below)
|
|
|
||||||
Loans receivables (*)
|
|
|
||||||
Other receivables
|
|
|
||||||
$
|
|
$
|
|
(*) |
On November 29, 2022, IMC Holdings signed on a convertible loan agreement with Telecana Ltd. (“Telecana”), a pharmacy for sell of medical Cannabis under which IMC Holdings granted a loan amounted to NIS
|
NOTE 7 - |
INVENTORY
|
December 31, 2024
|
||||||||||||
Capitalized costs
|
Fair valuation adjustment, net
|
Carrying value
|
||||||||||
Work in progress:
|
||||||||||||
Bulk cannabis
|
$
|
|
$
|
|
$
|
|
||||||
Finished goods:
|
||||||||||||
Packaged dried cannabis
|
|
|
|
|||||||||
Other products
|
|
|
|
|||||||||
Balance as of December 31, 2024
|
$
|
|
$
|
|
$
|
|
December 31, 2023
|
||||||||||||
Capitalized costs
|
Fair valuation adjustment, net
|
Carrying value
|
||||||||||
Work in progress:
|
||||||||||||
Bulk cannabis
|
$
|
|
$
|
|
$
|
|
||||||
Finished goods:
|
||||||||||||
Packaged dried cannabis
|
|
|
|
|||||||||
Other products
|
|
|
|
|||||||||
Balance as of December 31, 2023
|
$
|
|
$
|
|
$
|
|
NOTE 8 - |
INVESTMENT IN AFFILIATE
|
NOTE 9 - |
PROPERTY, PLANT AND EQUIPMENT, NET
|
Building and improvements
|
Equipment and furniture
|
Computer, software and equipment
|
Vehicles
|
Total
|
||||||||||||||||
Cost:
|
||||||||||||||||||||
Balance at January 1, 2023
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Additions during the year
|
|
|
|
|
|
|||||||||||||||
Foreign currency translation
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Balance at December 31, 2023
|
|
|
|
|
|
|||||||||||||||
Additions during the year
|
|
|
|
|
|
|||||||||||||||
Disposals
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Deconsolidation of Oranim
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Foreign currency translation
|
|
|
|
(
|
)
|
|
||||||||||||||
Balance at December 31, 2024
|
|
|
|
|
|
|||||||||||||||
Accumulated depreciation:
|
||||||||||||||||||||
Balance at January 1, 2023
|
|
|
|
|
|
|||||||||||||||
Depreciation during the year
|
|
|
|
|
|
|||||||||||||||
Foreign currency translation
|
(
|
)
|
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||||||
Balance at December 31, 2023
|
|
|
|
|
|
|||||||||||||||
Depreciation during the year
|
|
|
|
|
|
|||||||||||||||
Disposals
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Deconsolidation of Oranim
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||
Foreign currency translation
|
|
|
|
(
|
)
|
|
||||||||||||||
Balance at December 31, 2024
|
|
|
|
|
|
|||||||||||||||
Depreciated cost at December 31, 2024
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Depreciated cost at December 31, 2023
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
NOTE 10 - |
GOODWILL AND INTANGIBLE ASSETS, NET
|
Cultivations and processing licenses (*)
|
Customer relationships
|
Trade name
|
Goodwill
|
Other
|
Total
|
|||||||||||||||||||
Cost:
|
||||||||||||||||||||||||
Balance at January 1, 2023
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
PPA adjustments
|
|
|
|
|
|
|
||||||||||||||||||
Disposals
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||||||
Foreign currency translation adjustments
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||||||
Balance at December 31, 2023
|
|
|
|
|
|
|
||||||||||||||||||
Impairment (Note 19F2)
|
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||
Deconsolidation of Oranim
|
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||
Foreign currency translation adjustments
|
|
|
|
|
|
|
||||||||||||||||||
Balance at December 31, 2024
|
|
|
|
|
|
|
||||||||||||||||||
Accumulated amortization:
|
||||||||||||||||||||||||
Balance at January 1, 2023
|
|
|
|
|
|
|
||||||||||||||||||
Amortization during the year
|
|
|
|
|
|
|
||||||||||||||||||
Balance at December 31, 2023
|
|
|
|
|
|
|
||||||||||||||||||
Amortization during the year
|
|
|
|
|
|
|
||||||||||||||||||
Deconsolidation of Oranim
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||||||
Balance at December 31, 2024
|
|
|
|
|
|
|
||||||||||||||||||
Amortized cost at December 31, 2024
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Amortized cost at December 31, 2023
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
(*) |
The licenses consist of GMP and GDP licenses and they have indefinitely useful life.
|
NOTE 11 - |
LEASING
|
A. |
Right of use assets:
|
Premises
|
Vehicles
|
Total
|
||||||||||
Cost:
|
||||||||||||
Balance at January 1, 2023
|
$
|
|
$
|
|
$
|
|
||||||
Changes during the year:
|
||||||||||||
New leases
|
|
|
|
|||||||||
Termination of leases
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Currency translation adjustments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Balance at December 31, 2023
|
|
|
|
|||||||||
Changes during the year:
|
||||||||||||
New leases
|
|
|
|
|||||||||
Termination of leases
|
|
(
|
)
|
(
|
)
|
|||||||
Deconsolidation of Oranim
|
(
|
)
|
|
(
|
)
|
|||||||
Currency translation adjustments
|
(
|
)
|
|
|
||||||||
Balance at December 31, 2024
|
|
|
|
|||||||||
Accumulated depreciation:
|
||||||||||||
Balance at January 1, 2023
|
|
|
|
|||||||||
Changes during the year:
|
||||||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Termination of leases
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Currency translation adjustments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Balance at December 31, 2023
|
|
|
|
|||||||||
Changes during the year:
|
||||||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Termination of leases
|
|
(
|
)
|
(
|
)
|
|||||||
Deconsolidation of Oranim
|
(
|
)
|
|
(
|
)
|
|||||||
Currency translation adjustments
|
(
|
)
|
|
(
|
)
|
|||||||
Balance at December 31, 2024
|
|
|
|
|||||||||
Depreciated cost at December 31, 2024
|
$
|
|
$
|
|
$
|
|
||||||
Depreciated cost at December 31, 2023
|
$
|
|
$
|
|
$
|
|
NOTE 11 - |
LEASING (Cont.)
|
B. |
Operating lease liabilities:
|
Premises
|
Vehicles
|
Total
|
||||||||||
Balance at January 1, 2023
|
$
|
|
$
|
|
$
|
|
||||||
Changes during the year:
|
||||||||||||
New leases
|
|
|
|
|||||||||
Payment of lease liabilities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Interest on lease liabilities
|
|
|
|
|||||||||
Termination of leases
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Currency translation adjustments
|
|
(
|
)
|
(
|
)
|
|||||||
Balance at December 31, 2023
|
|
|
|
|||||||||
Changes during the year:
|
||||||||||||
New leases
|
|
|
|
|||||||||
Payment of lease liabilities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Interest on lease liabilities
|
|
|
|
|||||||||
Termination of leases
|
|
(
|
)
|
(
|
)
|
|||||||
Deconsolidation of Oranim
|
(
|
)
|
|
(
|
)
|
|||||||
Currency translation adjustments
|
(
|
)
|
|
|
||||||||
Balance at December 31, 2024
|
$
|
|
$
|
|
$
|
|
December 31
|
||||||||
2024
|
2023
|
|||||||
Current liability
|
$
|
|
$
|
|
||||
Non-current liability
|
|
|
||||||
Balance at December 31
|
$
|
|
$
|
|
C. |
Amounts recognized in statements of cash flow:
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Amortization of the right for use assets
|
$
|
|
$
|
|
$
|
|
||||||
Interest on lease liabilities
|
$
|
|
$
|
|
$
|
|
||||||
Payment of lease liabilities
|
$
|
|
$
|
|
$
|
|
D. |
Analysis of contractual payment dates of leasing liability at December 31, 2024:
|
Up to a year
|
$
|
|
||
Between 1-3 years
|
|
|||
Total (undiscounted)
|
$
|
|
NOTE 12 - |
TRADE PAYABLES
|
December 31,
|
||||||||
2024
|
2023
|
|||||||
Open accounts in Israel (*)
|
$
|
|
$
|
|
||||
Open accounts abroad
|
|
|
||||||
$
|
|
$
|
|
(*) |
Including outstanding amount related to management fee to be paid to entity controlled by main shareholders of the Company in total amount of $
|
NOTE 13 - |
OTHER CURRENT LIABILITIES
|
December 31,
|
||||||||
2024
|
2023
|
|||||||
Accrued expenses (*)
|
$
|
|
$
|
|
||||
Employees and payroll accruals
|
|
|
||||||
Government authorities
|
|
|
||||||
Related parties (**)
|
|
|
||||||
Advances from customers
|
|
|
||||||
Liability for restructuring
|
|
|
||||||
Other payables
|
|
|
||||||
$
|
|
$
|
|
(*) |
Including outstanding amount related to management fee to be paid to entity controlled by main shareholders of the Company in total amount of $
|
(**) |
On October 5, 2023, IMC Holdings entered into a loan agreements with two main shareholders, to borrow a principal amount of NIS
|
NOTE 14 - |
CREDITS FROM BANK INSTITUTION AND OTHERS
|
A. |
On May 17, 2023, the Company and Bank Mizrahi entered into credit facility with total commitment of up to NIS
|
B. |
On October 11, 2022, IMC Holdings entered into a loan agreement with non-financial institution, to borrow a principal amount of NIS
|
C. |
On October 17, 2023, IMC Holdings entered into a loan agreement with a non-financial institution, to borrow a principal amount of NIS
|
D. |
On October 11, 2023, IMC Holdings entered into a loan agreement with a non-financial institution, to borrow a principal amount of NIS
|
NOTE 14 - |
CREDITS FROM BANK INSTITUTION AND OTHERS (Cont.)
|
E. |
On October 11, 2023, IMC Holdings entered into a loan agreement with a non-financial institution, to borrow a principal amount of $
|
F. |
On October 9, 2023, Rosen entered into a loan agreement with a non-financial institution, to borrow a principal amount of NIS
|
G. |
On July 1, 2024, IMC Holdings entered into series of short-terms loan agreements with a non-financial institution, to borrow a principal amount of NIS
|
H. |
On February 28, 2024, a loan agreement was signed between IMC Holdings and Kadimastem Ltd. (“Kadimastem”) under which Kadimastem will provide a loan of up to US$
|
NOTE 14 - |
CREDITS FROM BANK INSTITUTION AND OTHERS (Cont.)
|
I. |
On July 30, 2024, the Company entered into an acknowledgment and payment schedule agreement with an unrelated service provider, regarding unpaid fees, charges, and disbursements for legal services rendered to the Company. According to the terms of the agreement, the Company is required to pay an amount of $
|
J. |
From time to time, in the normal course of business, the Company enters into financing transactions with non-banking credit services entities under which the Company receives short-term loans that are guaranteed by certain identified outstanding unpaid invoices of certain customers (the “Selected Trade Receivables”). As it was determined that the Company has retained substantially all the risks and rewards of ownership of the Selected Trade Receivables, the Company continues to recognize the Selected Trade Receivables in their entirety and recognizes financial liability for the consideration received as short-term loans.
|
December 31,
|
||||||||
2024
|
2023
|
|||||||
Credit from bank institution |
$
|
|
$
|
|
||||
Credit from non-financial institutions |
|
|
||||||
Check receivables
|
|
|
||||||
$
|
|
$
|
|
December 31,
|
||||||||
2024
|
2023
|
|||||||
Current maturity
|
$
|
|
$
|
|
||||
Long-term credit
|
|
|
||||||
$
|
|
$
|
|
NOTE 15 - |
CONVERTIBLE DEBENTURES OFFERING
|
Closing Date
|
||||
Debentures (host instrument)
|
$
|
|
||
Embedded conversion feature
|
|
|||
$
|
|
Debentures
|
||||
Balance at Closing Date
|
$
|
|
||
Issued
|
|
|||
Recognition of discount
|
(
|
)
|
||
Amortization of discount expenses
|
|
|||
Balance at December 31, 2024
|
$
|
|
NOTE 16 - |
DERIVATIVE WARRANTS LIABILITIES AND PREFUNDED WARRANTS
|
A. |
From time to time the Company entered into a non-brokered private placement offering transactions or settlement agreements under which the Company issued units that consist of common shares and warrants which are exercisable into common shares over a limited period of the time at an exercise price which is denominated in foreign currency and/or as the warrants might be exercisable to variable number of shares due to cashless exercise mechanism. As a result of the above, the warrants are accounted for as a derivative warrants liability which is measured at fair value through profits and losses.
|
December 31, 2024
|
December 31, 2023
|
|||||||||||||||||||
Series 2024
|
Series 2023
|
Series 2021
|
Series 2023
|
Series 2021
|
||||||||||||||||
Share price (in CAD)
|
|
|
|
|
|
|||||||||||||||
Exercise price (in CAD)
|
|
|
|
|
|
|||||||||||||||
Expected volatility (%)
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||||
Risk-free interest rate (%)
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||||
Dividend yield (%)
|
|
|
|
|
|
|||||||||||||||
Expected term (years)
|
|
|
|
|
|
|||||||||||||||
Number of warrants
|
|
|
|
|
|
|||||||||||||||
Fair value per warrant (in CAD)
|
|
|
|
|
|
Series 2024
|
Series 2023
|
Series 2021
|
Total
|
|||||||||||||
Balances at January 1, 2022
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Changes in fair value
|
|
|
(
|
)
|
(
|
)
|
||||||||||
Balances at December 31, 2022
|
|
|
|
|
||||||||||||
Issued (see Notes 18B5-18B6 below)
|
|
|
|
|
||||||||||||
Changes in fair value
|
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||||
Balances at December 31, 2023
|
|
|
|
|
||||||||||||
Issued (see Note 18B7 below)
|
|
|
|
|
||||||||||||
Changes in fair value
|
(
|
)
|
|
|
(
|
)
|
||||||||||
Balances at December 31, 2024
|
$
|
|
$
|
|
$
|
|
$
|
|
NOTE 17 - |
CONTINGENT LIABILITIES
|
A. |
Legal proceedings:
|
|
1. |
On July 11, 2021, the Company was informed that on June 30, 2021, a claim was filed to Beer Sheva Magistrate Court, by the municipal committee presiding over planning and construction in southern Israel against Focus, Focus’ directors and officers, including the main shareholders, and certain landowners, claiming for inadequate permitting for construction relating to the Focus Facility (the “Construction Proceedings”).
|
2. |
On November 19, 2021, Adjupharm filed a statement of claim (the “Claim”) to the District Court of Stuttgart (the “Stuttgart Court”) against Stroakmont & Atton Trading GmbH (“Stroakmont & Atton”), its shareholders and managing directors regarding a debt owed by Stroakmont & Atton to Adjupharm of approximately EUR
|
A. |
The contractual party of the Company was not the Stroakmont & Atton. The contract with Stroakmont & Atton was only concluded as a sham transaction in order to cover up a contract with a company named Uniclaro GmbH (“Uniclaro”). Therefore, Stroakmont & Atton is not the real purchaser rather than Uniclaro.
|
B. |
The Company allegedly placed an order with Uniclaro for a total of
|
NOTE 17 - |
CONTINGENT LIABILITIES (Cont.)
|
2. |
(Cont.)
|
|
NOTE 17 - |
CONTINGENT LIABILITIES (Cont.)
|
A. |
Legal proceedings (Cont.):
|
3. |
On December 22, 2022, Uniclaro filed a statement of claim against Adjupharm with the district court in Hamburg, pursuant to which Uniclaro is claiming the purchase price for
|
4. |
On November 17, 2023, the Company received a copy of a statement of claim that was filed in the Ontario Superior Court of Justice in Canada by 35 Oak Holdings Ltd., MW Investments Ltd., 35 Oak Street Developments Ltd., Michael Wiener, Kevin Weiner, William Weiner, Lily Ann Goldstein-Weiner, in their capacity as trustees of the Weiner Family Foundation (collectively the “MYM Shareholder Plaintiffs”) against the Company and its board of directors and officers (collectively, the “MYM Defendants”).
|
NOTE 17 - |
CONTINGENT LIABILITIES (Cont.)
|
B. |
Tax Remittance:
|
NOTE 18 - |
EQUITY
|
A. |
Composition of share capital:
|
December 31, 2024
|
December 31, 2023
|
|||||||||||||||
Authorized
|
Issued and outstanding
|
Authorized
|
Issued and outstanding
|
|||||||||||||
Number of shares
|
||||||||||||||||
Common Shares without par value
|
Unlimited
|
|
Unlimited
|
|
B. |
Changes in issued and outstanding share capital:
|
Number of shares
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Balance as of January 1
|
|
|
|
|||||||||
Common shares issued as settlement of purchase consideration through business combination transactions (1), (2), (3)
|
|
|
|
|||||||||
Issuance of treasury common shares
|
|
|
|
|||||||||
Common shares issued through private placements (4), (5), (7)
|
|
|
|
|||||||||
Common shares issued as debts settlement with related parties (5), (6)
|
|
|
|
|||||||||
Common shares issued as compensation to a related party (8)
|
|
|
|
|||||||||
Common shares issued upon options exercised (9)
|
|
|
|
|||||||||
Common shares issued upon RSUs vested (9)
|
|
|
|
|||||||||
Balance as of December 31
|
|
|
|
NOTE 18 - |
EQUITY (Cont.)
|
B. |
Issuance of common shares (Cont.):
|
1. |
On March 14, 2022, Yarok Pharm Transaction was closed upon receipt of all required approvals, including the IMCA approval. In connection with the closing of the Yarok Pharm Transaction, on the same date, the Company completed a non-brokered private placement with former shareholders of Yarok Pharm and Rosen High Way under which
|
2. |
On March 14, 2022, Vironna Transaction was closed upon receipt of all required approvals, including the IMCA approval. At the closing date, an amount of NIS
|
3. |
On March 28, 2022, Oranim Transaction was closed upon receipt of all required approvals, including the approval of the MOH. At the closing date, an amount of NIS
|
4. |
On August 19, 2022, the Company announced a private placement for aggregate gross proceeds of up to US$
|
5. |
In January and February of 2023, the Company issued
|
NOTE 18 - |
EQUITY (Cont.)
|
B. |
Issuance of common shares (Cont.):
|
6. |
(Cont.)
|
6. |
On May 8, 2023, the Company closed a debt settlement transaction (the “Debt Settlement”) with L5 Capital Inc., a company controlled by Marc Lustig, the then executive chairman of the Board of the Company (“L5 Capital”), pursuant to which the Company settled outstanding indebtedness of US$
|
7. |
On November 12, 2024, the Company closed a non-brokered private placement offering through issuance of
|
NOTE 18 - |
EQUITY (Cont.)
|
B. |
Issuance of common shares (Cont.):
|
8. |
Since October 2022, the Company has borrowed from various institutions more than US$
|
9. |
During the year ended December 31, 2022, the Company issued
|
NOTE 18 - |
EQUITY (Cont.)
|
C. |
Share-based payment
|
1. |
Share option plan
|
2. |
The following table presents the Company’s options activity under the 2018 Plan for the reported periods:
|
Year ended
December 31, 2024
|
||||||||
Number of options
|
Weighted average exercise price
|
|||||||
in CAD
|
||||||||
Options outstanding at the beginning of the year
|
|
|
||||||
Options granted during the year
|
|
|
||||||
Options forfeited during the year
|
(
|
)
|
|
|||||
Options outstanding at the end of year
|
|
|
||||||
Options exercisable at the end of year
|
|
|
Year ended
December 31, 2023
|
||||||||
Number of options
|
Weighted average exercise price
|
|||||||
in CAD
|
||||||||
Options outstanding at the beginning of the year
|
|
|
||||||
Options granted during the year
|
|
|
||||||
Options forfeited during the year
|
(
|
)
|
|
|||||
Options outstanding at the end of year
|
|
|
||||||
Options exercisable at the end of year
|
|
|
NOTE 18 - |
EQUITY (Cont.)
|
C. |
Share option plan (Cont.)
|
Year ended
December 31, 2022
|
||||||||
Number of options
|
Weighted average exercise price
|
|||||||
in CAD
|
||||||||
Options outstanding at the beginning of the year
|
|
|
||||||
Options granted during the year
|
|
|
||||||
Options exercised during the year
|
(
|
)
|
|
|||||
Options forfeited during the year
|
(
|
)
|
|
|||||
Options outstanding at the end of year
|
|
|
||||||
Options exercisable at the end of year
|
|
|
3. |
The following table presents the assumptions used to estimate the fair values of the options granted in the reported periods:
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Share price (in CAD)
|
$
|
|
$
|
|
$
|
|
||||||
Exercise price (in CAD)
|
$
|
|
$
|
|
$
|
|
||||||
Expected life (years)
|
|
|
|
|||||||||
Volatility (%)
|
|
|
|
|||||||||
Annual risk-free rate (%)
|
|
|
|
|||||||||
Dividend yield (%)
|
|
|
|
4. |
The following table presents the Company’s restricted share units (“RSUs”) activity under the 2018 Plan for the reported periods:
|
Number of RSUs
|
||||||||
2023
|
2022
|
|||||||
RSUs outstanding at the beginning of the year
|
|
|
||||||
RSUs exercised during the year
|
(
|
)
|
|
|||||
Outstanding at the end of the year
|
|
|
||||||
Exercisable at the end of year
|
|
|
5. |
As of December 31, 2024, there was $
|
NOTE 19 - |
ADDITIONAL INFORMATION TO PROFIT OR LOSS ITEMS
|
A. |
Additional information on revenue:
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Cannabis products
|
$
|
|
$
|
|
$
|
|
||||||
Other products
|
|
|
|
|||||||||
$
|
|
$
|
|
$
|
|
B. |
Cost of revenue:
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Salaries and related expenses
|
$
|
|
$
|
|
$
|
|
||||||
Materials
|
|
|
|
|||||||||
Write-off
|
|
|
|
|||||||||
Professional fees
|
|
|
|
|||||||||
Depreciation
|
|
|
|
|||||||||
Miscellaneous
|
|
|
|
|||||||||
$
|
|
$
|
|
$
|
|
C. |
Selling and marketing expenses:
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Salaries and related expenses
|
$
|
|
$
|
|
$
|
|
||||||
Advertising
|
|
|
|
|||||||||
Professional fees
|
|
|
|
|||||||||
Depreciation
|
|
|
|
|||||||||
Miscellaneous
|
|
|
|
|||||||||
$
|
|
$
|
|
$
|
|
D. |
General and administrative expenses:
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Salaries and related expenses
|
$
|
|
$
|
|
$
|
|
||||||
Insurance
|
|
|
|
|||||||||
Professional fees, net (*)
|
|
|
|
|||||||||
Depreciation
|
|
|
|
|||||||||
Impairment
|
|
|
|
|||||||||
Miscellaneous
|
|
|
|
|||||||||
$
|
|
$
|
|
$
|
|
(*) |
Includes management fee incurred indirectly through an entity controlled by the main shareholder. See Note 24B below.
|
NOTE 19 - |
ADDITIONAL INFORMATION TO PROFIT OR LOSS ITEMS (Cont.)
|
E. |
Restructuring expenses:
|
F. |
Other expenses:
|
1. |
Oranim Plus Pharm Ltd.
|
NOTE 19 - |
ADDITIONAL INFORMATION TO PROFIT OR LOSS ITEMS (Cont.)
|
F. |
Other expenses (Cont.):
|
1. |
Oranim Plus Pharm Ltd.
|
April 15,
|
December 31,
|
|||||||
2024
|
2023
|
|||||||
ASSETS
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash
|
$
|
|
$
|
|
||||
Trade receivables
|
|
|
||||||
Other current assets
|
|
|
||||||
Inventory
|
|
|
||||||
|
|
|||||||
NON-CURRENT ASSETS:
|
||||||||
Property, plant and equipment, net
|
|
|
||||||
Right-of-use assets, net
|
|
|
||||||
Intangible assets, net
|
|
|
||||||
Goodwill
|
|
|
||||||
|
|
|||||||
Total assets
|
$
|
|
$
|
|
LIABILITIES
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Trade payables
|
$
|
|
$
|
|
||||
Other current liabilities
|
|
|
||||||
Current maturities of operating lease liabilities
|
|
|
||||||
|
|
|||||||
NON-CURRENT LIABILITIES:
|
||||||||
Operating lease liabilities
|
|
|
||||||
Deferred tax liability, net
|
|
|
||||||
|
|
|||||||
Total liabilities
|
$
|
|
$
|
|
||||
Purchase consideration payable
|
$
|
|
$
|
|
||||
Put option liability
|
$
|
|
$
|
|
2. |
Panaxia
|
NOTE 20 - |
TAXES ON INCOME
|
A. |
Tax rates applicable to the Group:
|
1. |
The Company is subject to tax rates applicable in Canada. The combined federal and provincial rate for the reported periods is
|
2. |
The Israeli subsidiaries are subject to Israeli corporate income tax rate of
|
3. |
The German subsidiary is subject to weighted tax rate of approximately
|
B. |
Carryforward net operating losses for tax purposes:
|
C. |
Income tax expense (tax benefit):
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Current taxes
|
$
|
|
$
|
|
$
|
|
||||||
Deferred taxes, net
|
(
|
)
|
|
(
|
)
|
|||||||
Taxes on income from previous years
|
(
|
)
|
|
(
|
)
|
|||||||
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
NOTE 20 - |
TAXES ON INCOME (Cont.)
|
D. |
Reconciliation of tax expense (benefit) and the accounting loss multiplied by the Company's domestic tax rate for:
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Loss before income tax
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Statutory tax rate in Canada
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Increase (decrease) in income tax due to:
|
||||||||||||
Non-deductible expenses (non-taxable income), net for tax purposes
|
(
|
)
|
(
|
)
|
|
|||||||
Effect of different tax rates of subsidiaries
|
|
|
|
|||||||||
Adjustments in respect of current income tax of previous years
|
(
|
)
|
|
(
|
)
|
|||||||
Recognition of tax benefits in respect of losses incurred in previous years
|
|
|
|
|||||||||
Unrecognized tax benefit in respect of losses incurred for the year
|
|
|
|
|||||||||
Other adjustments
|
|
|
(
|
)
|
||||||||
Income tax expense (benefit)
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
NOTE 21 - |
DISCONTINUED OPERATIONS AND DECONSOLIDATION
|
NOTE 21 - |
DISCONTINUED OPERATIONS AND DECONSOLIDATION (Cont.)
|
November 6,
2022
|
||||
ASSETS
|
||||
CURRENT ASSETS:
|
||||
Cash
|
$
|
|
||
Trade receivables
|
|
|||
Other current assets
|
|
|||
Loans receivable
|
|
|||
Biological assets
|
|
|||
Inventories
|
|
|||
|
||||
NON-CURRENT ASSETS:
|
||||
Property, plant and equipment, net
|
|
|||
Right of use assets, net
|
|
|||
Intangible assets, net
|
|
|||
|
||||
Total assets
|
$
|
|
||
LIABILITIES
|
||||
CURRENT LIABILITIES:
|
||||
Trade payables
|
$
|
|
||
Bank loans and credit facilities
|
|
|||
Other current liabilities
|
|
|||
Current maturities of operating lease liabilities
|
|
|||
|
||||
NON-CURRENT LIABILITIES:
|
||||
Operating lease liabilities
|
|
|||
Deferred tax liability, net
|
|
|||
|
||||
Total liabilities
|
$
|
|
NOTE 21 - |
DISCONTINUED OPERATIONS AND DECONSOLIDATION (Cont.)
|
Period ended
November 6,
2022
|
||||
Revenue
|
$
|
|
||
Cost of revenue
|
|
|||
Gross profit before fair value adjustments
|
|
|||
Fair value adjustments:
|
||||
Unrealized change in fair value of biological assets
|
|
|||
Realized fair value adjustments on inventory sold
|
(
|
)
|
||
Total fair value adjustments
|
(
|
)
|
||
Gross profit
|
|
|||
General and administrative expenses
|
|
|||
Impairment of goodwill, intangible assets, right-of-use assets and fixed assets
|
|
|||
Selling and marketing expenses
|
|
|||
Restructuring expenses
|
|
|||
Share-based compensation
|
|
|||
Total operating expenses
|
|
|||
Operating loss
|
(
|
)
|
||
Finance expenses, net
|
(
|
)
|
||
Loss before taxes on income
|
(
|
)
|
||
Taxes on income
|
(
|
)
|
||
Net loss from discontinued operations, net of tax
|
$
|
(
|
)
|
Period ended
November 6,
2022
|
||||
Operating activities
|
$
|
(
|
)
|
|
Investing activities
|
$
|
(
|
)
|
|
Financing activities
|
$
|
(
|
)
|
NOTE 22 - |
NET LOSS PER SHARE
|
Year ended
December 31,
|
||||||||||||
2024
|
2023 (*)
|
|
2022 (*)
|
|
||||||||
Numerator:
|
||||||||||||
Net basic loss from continued operations attributable to shareholders of the Company
|
$
|
(
|
)
|
(
|
)
|
$
|
(
|
)
|
||||
Change in fair value of derivative warrant liability (see Note 16 below)
|
|
|
(
|
)
|
||||||||
Net diluted loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Denominator:
|
||||||||||||
Common shares used in computing basic net loss per share from continued operations
|
|
|
|
|||||||||
Common shares to be issued upon exercise of derivative warrant liability
|
|
|
|
|||||||||
Common shares used in computing diluted net loss per share from continued operations
|
|
|
|
|||||||||
Basic net loss per common share from continued operations
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Diluted net loss per common share from continued operations
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
(*) |
Include the effect of Reverse Share Split (see also Note 18A above).
|
NOTE 23 - |
OPERATING SEGMENTS
|
A. |
General information:
|
Israel
|
Germany
|
Adjustments
|
Total
|
|||||||||||||
Year ended December 31, 2024
|
||||||||||||||||
Revenue
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Segment loss
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
(
|
)
|
||||||
Unallocated corporate expenses
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||
Total operating loss
|
$
|
(
|
)
|
|||||||||||||
Depreciation and amortization
|
$
|
|
$
|
|
$
|
|
$
|
|
Israel
|
Germany
|
Adjustments
|
Total
|
|||||||||||||
Year ended December 31, 2023
|
||||||||||||||||
Revenue
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Segment loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
|||||
Unallocated corporate expenses
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||
Total operating loss
|
$
|
(
|
)
|
|||||||||||||
Depreciation and amortization
|
$
|
|
$
|
|
$
|
|
$
|
|
Israel
|
Germany
|
Adjustments
|
Total
|
|||||||||||||
Year ended December 31, 2022
|
||||||||||||||||
Revenue
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Segment loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
|||||
Unallocated corporate expenses
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||
Total operating loss
|
$
|
(
|
)
|
|||||||||||||
Depreciation and amortization
|
$
|
|
$
|
|
$
|
|
$
|
|
B. |
Major customers
During the year ended December 31, 2024, the Company had
|
NOTE 24 - |
BALANCES AND TRANSACTIONS WITH INTERESTED AND RELATED PARTIES
|
A. |
Balances and transactions:
|
December 31,
|
||||||||
2024
|
2023
|
|||||||
Other current assets - main shareholders (Note 6)
|
$
|
|
$
|
|
||||
Other current assets - former non-independent director (Note 6)
|
$
|
|
$
|
|
||||
Trade payables - related party (Note 12)
|
$
|
|
$
|
|
||||
Other current liabilities - related parties (Note 13)
|
$
|
|
$
|
|
||||
Convertible debentures issued to main shareholders (Note 15)
|
$
|
|
$
|
|
||||
Derivative warrants liabilities and prefunded warrants issued to main shareholders (Note 16)
|
$
|
|
$
|
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
General and administrative expenses - management fee (1)
|
$
|
|
$
|
|
$
|
|
||||||
Finance income (expense) - Interest in income on loans granted to (received from) main shareholders
|
$
|
(
|
)
|
$
|
|
$
|
|
|||||
Finance income - Revaluation of derivative warrants liabilities granted to main shareholders
|
$
|
|
$
|
|
$
|
|
||||||
Finance expenses - Revaluation of prefunded warrants granted by main shareholder
|
$
|
|
$
|
|
$
|
|
||||||
Finance expenses - Extension fee and discount amortization expenses in respect of convertible debentures granted to main shareholders
|
$
|
|
$
|
|
$
|
|
||||||
Finance expenses - Compensation expenses in respect of guarantees granted by main shareholder
|
$
|
|
$
|
|
$
|
|
(1) |
Include mainly compensation for management services incurred indirectly by an entity controlled by the main shareholder offset by income resulted from subleasing agreement executed between the parties.
|
NOTE 24 - |
BALANCES AND TRANSACTIONS WITH INTERESTED AND RELATED PARTIES (Cont.)
|
B. |
Compensation of key management personnel of the Group:
|
Year ended
December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Payroll and related expenses
|
$
|
|
$
|
|
$
|
|
||||||
Share-based compensation
|
$
|
|
$
|
|
$
|
|
||||||
Professional fees (*)
|
$
|
|
$
|
|
$
|
|
(*) |
Includes management fees charges during the years ended December 31, 2024, 2023 and 2022 of $
|
NOTE 25 - |
FINANCIAL INSTRUMENTS
|
A. |
Financial risk management
|
1. |
General
|
2. |
Financial risk factors
|
A. |
Unquoted equity instruments risk
|
B. |
Price risks of Company's common share
|
NOTE 25 - |
FINANCIAL INSTRUMENTS (Cont.)
|
A. |
Financial risk management (Cont.)
|
2. |
Financial risk factors (Cont.)
|
C. |
Liquidity risk
|
D. |
Credit risks
|
1. |
As of December 31, 2024, the cash is mostly deposited in various bank institutions in Israel and Germany. The management regularly evaluates the financial strength of the financial institutions with which the Company engages. Accordingly, the Company's management believes that the credit risk to these balances is low.
|
2. |
Below is the breakdown of the Company’s financial assets subject to credit risks:
|
December 31,
|
||||||||
2024 | 2023 | |||||||
Cash
|
$
|
|
$
|
|
||||
Restricted cash deposit
|
$
|
|
$
|
|
||||
Trade receivables
|
$
|
|
$
|
|
E. |
Currency rate risk:
|
NOTE 25 - |
FINANCIAL INSTRUMENTS (Cont.)
|
B. |
Fair value of financial instruments
|
C. |
A summary of financial instruments broken down by group:
|
December 31,
|
||||||||
2024
|
2023
|
|||||||
Financial assets measured at depreciated cost
|
||||||||
Cash
|
$
|
|
$
|
|
||||
Restricted cash deposit
|
|
|
||||||
Trade receivables
|
|
|
||||||
Other current assets
|
|
|
||||||
|
|
|||||||
Financial liabilities measured at depreciated cost
|
||||||||
Operating leasing liabilities (including current maturity)
|
|
|
||||||
Credit from bank institution and others (including current maturity)
|
|
|
||||||
Convertible debentures
|
|
|
||||||
Trade payables
|
|
|
||||||
Accrued purchase consideration liabilities
|
|
|
||||||
Other current liabilities
|
|
|
||||||
|
|
|||||||
Financial liabilities measured at fair value
|
||||||||
Put option liability
|
|
|
||||||
Derivative warrants liabilities and prefunded warrants
|
$
|
|
$
|
|
D. |
Company capital risk management policy
|
NOTE 26 - |
SUBSEQUENT EVENTS
|
A. |
On January 5, 2025, IMC Holdings entered into agreement with third party under which the rights (
|
B. |
In February 2025, Telecana repaid a principal loan granted in previous year to IMC Holdings in total amount of NIS
|
C. |
As noted in Note 14C above, on January 16, 2025, the IMC Holdings entered into a second amendment to an agreement with non-financial institution for extension of the maturity date of the loan amounted NIS
|
D. |
As Noted in Note 14F above, on January 30, 2025, Yarok Pharm entered into a first amendment to an agreement with non-financial institution under which it was agreed that principal amount of NIS
|
E. |
As noted in Note 14B above, on March 5, 2025, IMC Holdings entered into a fourth amendment to an agreement with non-financial institution for extension of the maturity date of the loan amounted to NIS
|
F. |
On February 1, 2025, Bank Mizrahi has been extending the short-term loan granted to the Company on a weekly basis.
|
G. |
On March 20, 2025, the Company and Bank Mizrahi signed an agreement under which it was agreed to refinance the short-term loan of NIS
|